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Abstract 
Globally, relapse caused by Plasmodium vivax malaria is estimated to contribute 
approximately 50% to the overall number of vivax infections. In South-East Asia, 
relapse rates commonly exceed 50%, making relapse as the main source of vivax 
illness. Recurrent episodes of febrile illness and hemolysis inflict a significant public 
health burden particularly in vulnerable groups such as pregnant women and young 
children. Multiple relapses may contribute substantially to the delayed morbidity and 
unappreciated mortality relative to falciparum malaria. Therefore, the radical cure of P. 
vivax malaria requires a combination of both blood schizontocides to achieve acute 
clinical cure, and hypnozoiticides to prevent relapses in the future. The World Health 
Organization (WHO) recommends the standard 14-day primaquine regimen in curing 
and preventing relapse from vivax malaria. Another 8-aminoquinoline derivative with 
prolonged elimination half-life, tafenoquine, also propose an alternative choice in 
radical therapy. The main research question is: what is the most effective treatment to 
achieve radical cure of Plasmodium vivax in Vietnam? 
In order to answer this question a series of studies and clinical trials were conducted in 
Vietnam and our findings point to these conclusions:  
1/ The short 7-day course of primaquine is an available, safe and highly efficacious 
antirelapse treatment that could improve the adherence of patients and hence the 
effectiveness of radical cure of vivax relapse.  
2/ The single dose of 300 mg tafenoquine, an 8-aminoquinoline drug, has similar 
antirelapse activity compared to primaquine. When administered with chloroquine, this 
hypnozoiticidal agent is a potential candidate in the malaria elimination era.  
iii 
 
3/ The prevalence and variants of G6PD deficiency determinants of hemolytic toxicity 
of 8-aminoquinolines in malaria endemic regions represent important factors to be 
considered when implementing radical cure of latent vivax malaria.  
iv 
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Chapter 1 
Introduction 
1.1         Epidemiology of vivax malaria 
1.1.1       History of vivax malaria 
Human malaria is a parasitic disease that is endemic in most tropical and subtropical 
ecosystems worldwide. Malarial parasites belong to the genus Plasmodium and infect 
many vertebrate hosts, including several species of non-human primate. These parasitic 
protozoa have complex life-cycles that involve sexual reproduction in the mosquito 
vector and asexual stages in the vertebrate host [1]. Plasmodium vivax (P. vivax) 
originated from a malarial parasite of non-human primates as a result of a host switch, 
probably from a macaque. Plasmodium cynomolgi, a parasite found in macaques, is the 
closest sister species to P. vivax [2]. Another parasite, Plasmodium simium was 
sequenced to show that it is identical to that of P. vivax. Although P. simium was 
previously considered to be a monkey-specific species in South America, the 
transmission from a monkey reservoir to human beings could pose challenges in 
eliminating malaria in these regions [3].  
1.1.2 Current vivax malaria situation in the world 
P. vivax is a major public health challenge for Central and South America, the Middle 
East, Central, South and Southeast Asia, Oceania and East Africa, where 2.85 billion 
people are currently at risk of infection and 70-80 million clinical cases are reported 
each year. Important variances in the biology of P. vivax and P. falciparum render their 
epidemiology distinctly different. This leads to the wider geographic distribution of P. 
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vivax into temperate climate regions [4]. The most apparent is the ability of P. vivax to 
cause relapses weeks to months following the primary infection by activation of 
dormant liver-stage parasites, known as hypnozoites. There also exist differences in 
blood-stage dynamics that impact P. vivax epidemiology. Natural immunity is acquired 
at a younger age than against P. falciparum, making infants the primary risk group for 
severe vivax malaria in heavily endemic settings. While, in low-transmission settings, 
where P. vivax often persists against elimination efforts, all age groups appear at risk 
of severe disease [5, 6]. The propensity for P. vivax to invade young blood cells 
(reticulocytes) and the number of reticulocytes are generally around 0.5 – 1.5% of the 
total circulating erythrocytes result in relatively low levels of parasitaemia. Even in 
low-transmission settings, most infections appear to be microscopically sub-patent and 
asymptomatic [4].  
The geographic distribution of P. vivax infection and differences in relapse phenotype 
are illustrated and described alongside estimates of P. vivax burden, as well as severe, 
lethal, and chloroquine-resistance vivax malaria to demonstrate that control and 
elimination strategies developed for P. falciparum cannot simply be transferred to P. 
vivax.  
P. vivax depends on the Duffy antigen to invade red blood cells. Individuals who do not 
express the Duffy antigen have, therefore, been considered refractory to P. vivax 
infection and the prevalence of Duffy negative populations must be considered in 
predictions and maps of P. vivax endemicity [4]. Levels of P. vivax endemicity vary 
widely among the World Health Organization (WHO) regions. Outside of Africa, P. 
vivax is the dominant species, with relatively high prevalence of infection in the South-
East Asian and Western Pacific regions. Relatively high endemicity also occurs in most 
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of the Americas, but in much less densely populated areas. Data from which to estimate 
the geographic extent of P. vivax transmission in Africa are limited. High P. falciparum 
endemicity in much of that continent coupled with high prevalence of Duffy negativity 
overshadowed collection of P. vivax specific data as a priority. However, P. vivax 
infection in Africa has been increasing from several surveys suggesting the P. vivax 
endemicity in this continent may have been underestimated previously [7].  
Compared with similar predictions for P. falciparum, relatively low prevalence occurs 
throughout endemic world. There are other reasons why PvPR (parasite rate) could be 
lower than Pf PR. Although the prevalence of P. vivax in heavily endemic areas may 
reach or even exceed that of P. falciparum, P. vivax can often go undetected [8]. Low 
parasite densities lead to high rates of false-negative diagnoses by microscopy or rapid 
diagnostic tests (RDTs). Microscopy diagnosis underestimates the true prevalence of 
blood-stage P. vivax in both high- and low-transmission settings. Plasmodium vivax in 
mixed infections is also often underdiagnosed; lower densities of P. vivax in peripheral 
blood translate into P. falciparum being diagnosed before P. vivax is spotted by the 
microscopist. Another consideration with regard to true versus observed prevalence is 
the invisibility of the dormant liver stages to any diagnosis. These parasites could be 
highly prevalent in many endemic settings. All of these findings recommend caution in 
comparing prevalence estimates of P. vivax and P. falciparum based largely on blood-
stage infections diagnosed by relatively insensitive means. These may underestimate 
true prevalence of P. vivax far more than P. falciparum.  
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1.1.3 Relapse epidemiology 
The hypnozoites cause multiple clinical attacks from a single bite of a P. vivax-infected 
mosquito. In contrast, P. falciparum infection of the liver yields a single blood-stage 
infection [4]. In other words, “infection” as an event in P. falciparum is singular and 
clear, whereas the same in P. vivax takes on complex plurality and ambiguity in an 
epidemiological sense. Recurrence of asexual P. vivax parasites in peripheral blood may 
derive from three distinct sources: relapse (from hypnozoites), recrudescence (from 
sub-patent asexual parasitaemia), or reinfection (by new mosquito inoculation of 
sporozoites). Relapse may well be the predominant origin of most P. vivax clinical 
attacks throughout the endemic world. Geographical variation in the rate and timing at 
which a “strain” of P. vivax may relapse has long been known. Temperate and 
subtropical strains of the parasite exhibit either a long incubation period or a long delay 
between the primary infection and relapse (around 8-10 months). Tropical strains are 
characterized by short incubation times and short relapse intervals. The Americas, 
South East Asia, and Western Pacific WHO regions all harbor strains that relapse 
quickly and repeatedly following primary infection. The Indian subcontinent and sub-
Saharan Africa have variable relapse frequencies and periodicity, but show moderate 
time to relapse overall. Longer times to relapse are shown in areas around the 
Mediterranean and Central America, with the longest periods of latency in China and 
the Korean Peninsula [9, 10]. Regionally specific relapse patterns should be considered 
when assessing control and elimination strategy and tactics. Effects may be slowest to 
materialize in regions characterized by long-latency strains or high rates of relapse 
(even in areas with shorter latency). 
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Since the 1990s, Viet Nam has gained a remarkable success in controlling the morbidity 
and mortality associated with malaria. In annual reports from National Malaria Control 
Programme, the significant decline of malaria cases by 97% and deaths by 99.8% has 
been notified between 1991 and 2014 [11]. These reductions both in morbidity and 
mortality might have been attributable to a relatively strong malaria control programme, 
accessible health care facilities, and socio-economic improvements [12]. Currently, 
malaria transmission, with highest incidence, has been reported mostly in forested, 
border areas in Central and Central-Southern Viet Nam [13]. Following the successful 
control efforts against P. falciparum, the frequency of P. vivax relative to P. falciparum 
infection has increased in recent years, from 20% in 1991 to nearly 50% in 2015 [11]. 
Located in the Greater Mekong Subregion (GMS) and belonging to the Western Pacific 
Region of WHO, the relapse pattern of P. vivax malaria has been classified as frequent. 
In consequence, after the initial episode of acute vivax infection, the subsequent 
reappearance of parasitaemia usually occurs within 3 to 8 weeks [5] 
1.2 Malaria parasite 
1.2.1 Parasite life cycle  
Plasmodium vivax has unique attributes to support its survival in varying ecologies and 
climates. These include dormant hypnozoite forms in the liver, an invasion preference 
for reticulocytes, caveola–vesicle complex structures in the infected erythrocyte 
membrane and rapidly forming and circulating gametocytes. These characteristics 
make this species very different from P. falciparum, which combine to make the P. 
vivax relatively difficult to control and eliminate. In general terms, the life cycle of P. 
vivax is like that of all of the other primate malaria species in that it requires an 
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invertebrate and a vertebrate host for survival and sexual reproduction; a female 
mosquito of a susceptible Anopheles species serves as definitive host whereas primates 
are intermediate host. When the female mosquito bites, she releases salivary fluid and 
along with it a typically small number of sporozoites (e.g., < 10) from her salivary 
glands. In the dermal tissues, the sporozoites are motile and capable of penetrating small 
blood vessels, and there begin stimulating a host immune response [14]. In the 
circulating blood, they are swept into the liver sinusoid vessels where they penetrate 
through the professional phagocytes known as Küpffer cells into the Space of Disse to 
begin the exoerythrocytic or liver-stage cycle of growth. Once there, the sporozoite then 
penetrates a hepatocyte, rounds up and differentiates into a small trophozoite (∼4 μ in 
diameter) growing in size over the next few days eventually differentiating into a 
multinucleated schizont in 5 days. By 6 or 7 days, of primary growth and development, 
a fully mature schizont 40–60 μ in diameter has differentiated into thousands of 
individual invasive single nucleated merozoites surrounded by a parasitophorous 
membrane capsule. The plasma membrane of an infected hepatocyte breaks down, and 
blebs of the parasitophorous membrane full of merozoites called merosomes break off 
and flow into the circulation of the liver sinusoid vessels. These merosomes are carried 
into the faster flowing general blood circulation and break apart releasing the 
merosomes-incarcerated merozoites, which then attach to and invade red blood cells 
(RBCs) to start the erythrocytic cycle of asexual reproduction, also called blood 
schizongony. The newly invaded merozoite immediately differentiates into an 
erythrocytic trophozoite and begins remodelling the anucleate RBC to provide a 
suitable environment for it to grow larger over a period of 48 hours feeding upon the 
haemoglobin of the parasitised RBC. Thirty-eight or 40 h into this cycle of growth, the 
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nucleus divides in two to create a schizont and over the next 8 or so hours continues to 
divide by schizogony to form 12–16 or more differentiated merozoites in the case of P. 
vivax. When the host cell membrane ruptures after 48 h of parasite intracellular growth, 
the merozoites are released and invade new RBCs to begin the entire asexual blood 
cycle again. The merozoites in some schizonts are preprogrammed to differentiate into 
sexual-stage male or female micro- and macro-gametocytes, respectively, and not into 
asexual trophozoites upon entry into a new RBC. The insect or sexual stage of the life 
cycle begins when a feeding female Anopheles mosquito takes up some of these 
circulating male and female gametocytes in her blood meal. In the midgut of the blood-
engorged mosquito, the gametocytes lose their RBC membrane outer cover and become 
sexually active. The nucleus of the microgamete fractures into eight nuclei and eight 
flagellating bodies are formed. When one penetrates a macrogamete, a diploid zygote 
is formed that over a period of 24–36 h metamorphoses into an ookinete, another tissue 
invasive parasite stage. The ookinete penetrates through the mosquito midgut lining to 
lodge under the basal membrane where it transforms into an oocyst that undergoes 
multiple nuclear divisions to form a capsule of several thousand elongated sporozoites. 
At maturity, the capsule breaks open, releasing the thousands of sporozoites into the 
haemocoel of the mosquito, which then migrate to and penetrate the salivary glands to 
lodge in the glandular spaces waiting until the mosquito probes dermal tissue seeking a 
blood meal [14]. 
1.2.2 The Hypnozoite 
When a sporozoite of a relapsing malaria parasite enters the liver, it will differentiate 
into an early small liver trophozoite of about 4.0 or 5.0 μ in size and then it may enter 
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either of two very different developmental pathways. Firstly, there can be immediate 
growth in the host liver cell all the way through to schizogony and the production of 
thousands of merozoites that will initiate the erythrocytic cycle, as above. Alternatively, 
the small trophozoites become dormant hypnozoites and may remain in this quiescent 
metabolic state for weeks, months or up to 2 years in host liver [15].  
1.2.3 The Reticulocyte as a Host Cell 
For P. vivax dependent on reticulocyte host cells, an efficient process must ensue, 
enabling these organisms with the ability to effectively find and latch onto the limited 
number of young RBCs amidst a virtual sea of more mature erythrocytes. Generally, 
reticulocytes only make up 0.5–2.0% of the erythrocytes in circulation. A few proteins 
have so far been identified and characterized as being required during the invasion 
process of the reticulocyte by the merozoite. The reticulocyte-binding proteins have 
been defined as critical proteins that select these host cells in the circulation. The 
parasite’s Duffy Binding Protein has also been recognized for several decades as a 
critical RBC adhesion; only recently have P. vivax infections been associated with 
individuals with Duffy-negative RBC phenotypes [16, 17]. Restricting an infection to 
these young RBCs, which typically represent 0.5–2% of the circulating RBCs, may 
limit the rise in parasitaemia, but this strategy may also enable P. vivax to alter the 
infected RBCs (iRBCs) to remain or become more flexible and able to circulate through 
small capillary vessels and more likely to survive passage through the sinusoidal 
vasculature of the spleen.  
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1.2.4 The Sexual Life Strategies of P. vivax 
P. vivax gametocytes are known to develop early in an acute primary infection, within 
5 days of the clinical onset. In fact, gametocytes are known to be produced earlier, 
perhaps, within 8 days after mosquito inoculation before they can be seen by light 
microscopy as mosquitoes can become infected at this time. Gametocyte densities 
become greater as blood-stage infections progress, seeming to come in waves at 5-day 
intervals and the production of gametocytes continues as the infection progresses on 
into chronicity becoming asymptomatic or more mildly symptomatic [18]. This ability 
to form infective gametocytes early and continuously, in addition to the periodic 
renewal of blood infections (and gametocyte propagation) by reactivated hypnozoites, 
makes P. vivax transmission fast, efficient and persistent. Like the asexual stages, the 
P. vivax-gametocyte-infected erythrocyte, which continues to circulate in the blood and 
not become immobilized in a tissue site as P. falciparum gametocytes do, remains 
highly flexible and capable of passing through small capillaries or splenic sinusoidal 
vessels despite containing a large parasite body [19]. There are many Anopheline 
mosquito species in the tropical, sub- tropical and, most illustratively, in the temperate 
latitudes quite far north that can act as efficient and effective transmitters of P. vivax 
[20]. The biological attributes of sporozoite development over a large temperature 
range in an array of susceptible mosquito vector species that over winter combined with 
delayed relapse genotypes/phenotypes allow the successful transmission of P. vivax 
[21, 22].  
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1.3 Pathophysiology of vivax malaria 
There are a number of differences in pathobiology between P. vivax and P. falciparum 
that are important in understanding the pathophysiology of vivax malaria.  
1.3.1 Parasite biomass 
Plasmodium falciparum invades RBC of all ages, and progresses to high parasite 
burdens if uninhibited by treatment or host immunity, with parasite biomass a major 
independent determinant of the risk of death [23]. In contrast, P. vivax has a very strong 
predilection for infecting RBCs that have emerged from the bone marrow within the 
last 14 days. This property contributes to the lower parasite biomass seen in P. vivax 
infections. Unlike P. falciparum infections, parasitaemia in vivax malaria rarely exceed 
2% of circulating RBCs [24].  
1.3.2 Relapse 
A fundamental difference between P. falciparum and P. vivax is the ability of P. vivax 
to relapse from dormant hypnozoites and cause repeated episodes of clinical and 
subclinical infections. Differences in relapse patterns may be a major contributor to the 
geographic variation in vivax morbidity and disease severity. In tropical regions, P. 
vivax is characterized by frequent relapses 3–6 weeks apart, resulting in recurrent 
infections often with heterologous strains to which there is little cross-immunity. 
Frequent recurrent infections prevent adequate time for the patient to achieve 
haematological recovery from each bout of haemolysis. In contrast, in temperate areas, 
relapses are fewer and delayed, and the associated impact of each recurrence is less 
[25].  
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1.3.3 Greater inflammatory response in P. vivax than P. falciparum 
Plasmodium vivax has a lower pyrogenic threshold than P. falciparum. Cytokine 
production, endothelial activation and pulmonary inflammatory responses are higher 
during and after P. vivax infections than in P. falciparum infections of similar parasite 
biomass [24]. Although the inflammatory process correlates of the lower pyrogenic 
threshold have been reported, the underlying mechanism has not identified. 
In falciparum malaria, plasma concentrations of the pro-inflammatory cytokine tumor 
necrosis factor (TNF) and the anti-inflammatory cytokine interleukin-10 (IL-10) are 
directly related to disease severity. Although P. vivax is capable of eliciting greater 
concentrations of both pro- and anti-inflammatory cytokines than P. falciparum, the 
relationships to disease severity are different in vivax malaria. While plasma 
concentrations of the pro-inflammatory cytokines TNF and gamma interferon (IFN-)  
are directly related to disease severity, plasma concentrations of IL-10 are inversely 
related to vivax disease severity, suggesting a deficiency in the anti- inflammatory 
response in severe vivax malaria, with an unopposed pro- inflammatory response [26]. 
Plasma concentrations of superoxide dismutase, an enzyme produced in response to 
oxidative stress, have also been associated with vivax disease severity, but a role in 
pathogenesis has not been determined [27]. Another putative toxin that appears unique 
to P. vivax is a lipid found in the cholesterol/triglyceride fraction of plasma at the time 
of paroxysmal fever. This lipid has greater activity than phospholipids, and together 
with host cytokines, is known to mediate in vitro aggregation of leucocytes, mostly 
neutrophils. This lipid may also contribute to the greater pyrogenicity of P. vivax [28].   
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1.3.4 Cytoadherence and rosetting 
A central mechanism in the pathophysiology of severe falciparum malaria is the 
cytoadherence of late stages of P. falciparum to activated microvascular endothelium 
resulting in sequestration and microvascular obstruction [29]. Since all stages of P. 
vivax are visible in peripheral blood, albeit with partial depletion of mature stages, 
sequestration is not thought to occur to a significant degree in vivax malaria or cause 
end-organ dysfunction in the same manner as P. falciparum [30]. Recent in vitro data 
show that P. vivax-infected RBCs do cytoadhere to endothelial cells, via ICAM-1 and 
chondroitin sulphate-A (CSA), with a similar strength but a 10-fold lower frequency 
than P. falciparum-infected RBCs [31]. Another study showed no cytoadherence to 
ICAM-1 but did confirm cytoadherence to the glycosaminoglycans, CSA and 
hyaluronic acid [32]. Rosetting, adherence of non-infected to infected RBCs, has been 
linked to the pathophysiology of severe falciparum malaria. Rosetting has been 
described ex vivo in vivax malaria, however, its role in vivax pathophysiology is 
unknown [33, 34]. 
1.3.5 Endothelial activation and altered thrombostasis 
Concentrations of circulating endothelial activation markers are as high (ICAM-1 and 
E-selectin) or higher (angiopoietin-2) in uncomplicated vivax malaria than in 
falciparum malaria. Endothelial dysfunction and impaired NO bioavailability are 
significant contributors to severe falciparum malaria, but their importance in severe 
vivax malaria is not known [35]. Other consequences of endothelial activation and 
altered thrombostasis may be more important in P. vivax infection. The role of altered 
haemostatic pathways, intravascular coagulation and endothelial inflammation through 
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increased formation of ultra-large Von Willebrand factor and platelet aggregates in 
severe vivax malaria is not known. However, with the reports of thrombotic 
microangiopathy in some cases, vivax-associated kidney disease, these processes may 
contribute to at least a proportion of vivax associated acute kidney injury, coma, 
anaemia and/or thrombocytopenia [36]. 
1.4 Diagnosis of vivax malaria 
1.4.1 Clinical diagnosis 
The spectrum of disease associated with P. vivax infection ranges from asymptomatic 
parasitaemia and uncomplicated febrile illness through to severe and fatal malaria [24]. 
Clinical diagnosis of vivax malaria is difficult because signs and symptoms are non-
specific and impacted by endemicity and host immunity. Common symptoms include 
malaise, fever, chills, diaphoresis, headache, arthralgia, myalgia, cough, abdominal 
pain, nausea, vomiting, and diarrhea, which can also occur with many common 
systemic febrile illnesses such as meningitis, pneumonia or gastroenteritis. 
Splenomegaly, anaemia, leukopenia and thrombocytopenia are also common, but non-
specific. Infection of a non-immune host results in a prodromal period followed by an 
acute fever. Prodromal symptoms can include increasing headache, anorexia, malaise, 
myalgias and/or gastrointestinal symptoms for one or more days, sometimes with 
periodicity. A low-grade prodromal fever without paroxysmal symptoms may also 
occur. The ‘paroxysm’ has long been recognized as the periodic febrile response to 
Plasmodium infection occuring following rupture of schizont-infected red cells. The 
paroxysm is classically, but not invariably, preceded by a ‘cold stage’ of chills and a 
rigor. A chilly sensation proceeds to shivering and then intense muscle tremors, 
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chattering of teeth and sometimes violent shaking. The temperature rises before the 
rigor ceases. Defervescence is accompanied by sweating and fatigue [24]. Respiratory 
symptoms have long been recognized as common in vivax malaria. Cough, usually non-
productive, occurs in approximately half of the adults with vivax malaria, in residents 
of both vivax- endemic and -non-endemic areas [37]. Tachypnoea may occur because 
of high fever, anaemia and/or pulmonary pathology. 
Depending on where infection is acquired, the differential diagnosis should also include 
dengue fever, typhoid fever (particularly in south central Asia), infectious 
mononucleosis, rickettsiosis, influenza, and bacteremia and region-specific arboviral 
infections.  
1.4.2 Microscopic diagnosis 
Diagnosis of vivax malaria should be established by microscopic examination of 
Giemsa-stained thick and thin smear blood samples obtained every 8-12 h over a 24-48 
h period [38]. Clinical signs and symptoms alone, though frequently used, can neither 
differentiate malaria infection from other causes of febrile illness, nor distinguish 
between P. falciparum and P. vivax or malaria caused by another plasmodia. 
Examination of at least 200 fields of a thick blood film under oil immersion 
magnification (x 1,000) should be undertaken before a negative diagnosis is made [39]. 
The limit of detection for expert microscopists is considered to be about 10-20 
parasites/uL. The density of parasitaemia in patients with acute vivax malaria depends 
upon many factors, including naïve versus a state of semi-immunity, age, delay in 
seeking treatment, self-treatment behavior before presentation, and likely a variety of 
host and parasite factors. The parasite density in P. vivax malaria is typically and order 
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of magnitude lower than P. falciparum in most clinical settings where both these 
species occur, thus increasing the risk of false negative microscopy diagnosis with acute 
vivax malaria [8].  
1.4.3 Antigen-capture rapid diagnostic testing 
Malaria rapid diagnostic tests (RDTs) composed of immunochromatoghraphic lateral 
flow devices, are qualitative diagnosis tools to detect antigens derived from parasite 
antigens in patient blood. The principal advantage of RDTs is their ease of use and 
sustainability in resource-challenged settings. RDTs are available from many 
commercial sources at relatively low cost (usually < US$1/test) [40]. Most of these kits 
are stable at ambient temperature storage for many months. In 2002, WHO began to 
develop malaria RDT evaluation programme to ensure the quality control among 
different kits of RDTs. The parasite detection score is a measure of inter-test and inter-
lot consistency. For P. falciparum, the detection score indicates an RDT result 
confirming the presence of P. falciparum, when tested against cultured and wild-type 
P. falciparum samples. While, the P. vivax detection score indicates P. vivax-positive/ 
P. falciparum negative results when tested on wild-type P. vivax samples [40]. In 
general, the kits perform better with P. falciparum infection than that with P. vivax 
(e.g., 74% versus 37% of test brands scored > 75% “parasite detection score” at a 
density of 200 parasites/uL, respectively) [41]. Some tests detect P. falciparum 
histidine-rich protein 2 (HRP-2) in addition to a pan-genus antigen (lactate 
dehydrogenase [pLDH]). Reaction to both indicates presence of P. falciparum, either 
alone or mixed with any other species, whereas reaction to pLDH alone indicates 
absence of P. falciparum and presence of any other species. Other RDTs do offer a P. 
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vivax-specific diagnosis employing aldolase antigen capture with satisfactory 
performance [41]. If available, an antigen-capture RDT, which can distinguish 
falciparum form non-falciparum malaria, may be helpful for establishing early 
diagnosis when microscopic diagnosis capabilities are not available. Currently, the only 
US Food and Drug Administration (FDA) approved RDT is the Binax NOW Malaria 
Test, a card-based diffusion immunochromatoghraphic assay which detects the 
presence of P. falciparum-specific histidine-rich protein 2 (HRP-2) and a pan-malarial 
antigen common to all four human species. When used in endemic locations where 
prevalence of malaria is high, the overall sensitivities and specificities for P. falciparum 
exceeded 95%, while performance for diagnosis of P. vivax is much lower, sensitivity 
69% and specificity 100%, and does not meet the WHO recommended minimum panel 
detection score [41]. Because RDT sensitivity is directly related to parasite density, 
health care providers cannot rely on a negative RDT result to rule out malaria, 
particularly for vivax malaria. However, a positive result may be helpful in making 
management decisions before a microscopic diagnosis can be made [38]. In Vietnam, 
the current available malaria rapid diagnostic test using in health facilities is SD Bioline 
Malaria Ag P. falciparum/P. vivax, which is supported by the Global Fund. The test 
measures the presence of HRP-2 antigen specified for P. falciparum and pLDH 
specified for P. vivax.  
1.4.4 Molecular diagnosis 
The most widely applied and validated molecular diagnostic is a nested polymerase 
chain reaction (PCR) amplification of small subunit ribosomal RNA gene sequences. 
The term nested refers to an initial amplification using primers of genus-wide sequences 
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followed by primers of species-specific character to provide the definitive diagnosis. 
This technique, and other PCR-based approaches to diagnosis, requires relatively 
advanced laboratory equipment and technologically skilled execution. Typically, blood 
blots dried onto filter paper in the field are transported to a laboratory where extraction 
of DNA and its analysis by PCR is performed. It is also relatively expensive at tens of 
dollars per test on most platforms. The advantage of PCR is increased sensitivity to 
detect parasitaemia up to three orders of magnitude lower (depending on blood volume 
sampled) compared with microscopy or RDT. Its absolute sensitivity in operational use 
is approximately 1.0 parasite/uL, increasing to 0.02 parasites/uL if > 0.25 ml of venous 
blood can be collected [42].  
1.4.5 Loop-mediated isothermal amplification (LAMP) 
LAMP of parasite-specific DNA is a more recent technology more suited to active case 
detection in endemic settings. The technique does not require expensive thermocyclers 
or gel electrophoresis, the readout being a visual color change in a small test tube [43]. 
Recent evaluation of a commercially available kit showed the technique to be 
comparable to standard nested PCR technique and superior to expert microscopy. The 
procedure can be completed in about 1 hour at the site of collection [44]. Deployment 
of LAMP-based diagnostics to low resource settings and further evaluation of 
sensitivity and specificity outside of the research setting is necessary before widespread 
use or replacement of microscopic diagnosis with LAMP can be recommended. 
1.5 Treatment of vivax malaria 
The goals of antimalarial treatment in P. vivax are to reduce the immediate risk to the 
patient, eradicate peripheral asexual parasitaemia, prevent the recurrent infection, and 
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interrupt the cycle of transmission. The ability of P. vivax to form dormant liver stages 
(hypnozoites) capable of causing relapsing infections weeks to months after the initial 
blood-stage infection, provides a major challenge to the complete eradication of 
parasites from the body (radical cure). Since no single drug achieves all of these aims, 
a combination of antimalarials is required targeting a variety of specific key elements 
of the parasite life cycle. Treatment of infection by P. vivax imposes far greater 
complexity, nuance, and risk to the patient relative to treatment of uncomplicated 
falciparum malaria. Treating both liver and blood stages, as opposed to blood stages 
alone, greatly amplifies the complexity of the chemotherapeutic problem [38].  
1.5.1 Treatment of asexual erythrocytic stages of P. vivax 
1.5.1.1 Treatment of uncomplicated vivax malaria 
Chloroquine has been the treatment of choice for P. vivax malaria for almost 70 years 
[38]. By the 1940s, clinical studies confirmed chloroquine to be an extremely potent 
antimalarial agent, effective against all plasmodia species, and its slow elimination from 
the blood allowing curative regimens to be achieved with short-course treatment 
regimens. Clinical experience in a huge number of patients demonstrated the drug to be 
safe and well-tolerated, including its use in pregnant women and young infants. 
Chloroquine is rapidly absorbed after oral administration, its bioavailability exceeding 
90% [45]. It has an extremely long and complex terminal elimination phase because of 
its extensive distribution in tissue, with high concentrations occurring in the liver, 
spleen, kidney, and lung. This tissue penetration accounts for its enormous apparent 
volume of distribution (~200-300 l/kg), and it is this rather than the elimination process 
that determines the blood concentration profile of this drug. Its reported half-life varies 
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from 70 to 300 h, resulting in therapeutic drug concentrations being detected in the 
blood for between 3 weeks and 3 months after administration in some patients. Against 
sensitive strains of P. vivax, chloroquine produces a very rapid clinical and 
parasitological response, patients usually clearing their fever and peripheral 
parasitaemia within 48 h. Chloroquine, similar to all blood schizontocidal agents 
effective against P. vivax, is gametocytocidal with rapid clearance of sexual stages 
during acute infection. Its slow elimination provides a period during which blood 
concentrations exceed the minimally effective concentration of the parasites, ensuring 
complete clearance of all erythrocytic stages of the parasite and providing a prolonged 
period of post-treatment prophylaxis (PTP) during which the drug can suppress new 
invasion of the blood stream by merozoites from reinfection or relapse from 
hypnozoites [38]. Although chloroquine has dominated antimalarial treatment of P. 
vivax for over half a century, this position is under threat from the emergence and spread 
of chloroquine-resistant strains of the parasite. The first cases of chloroquine-resistant 
P. vivax were documented in 1989, almost 30 years after reports of the emergence of 
chloroquine-resistant P. falciparum [46]. In areas where P. vivax is known to be 
chloroquine (CQ) sensitive, the WHO recommends 3 days of CQ or an artemisinin 
combination treatment plus 2 weeks of primaquine (PQ) (provided the affected 
individual is not G6PD deficient) [45]. CQ remains a first-line treatment in most parts 
of the world due to its wide availability, low cost, and long terminal elimination half-
life. However, in co-endemic malarious areas, this necessitates a separate treatment 
approach for P. falciparum and P. vivax.  Artemisinin combination therapies (ACTs) 
are the treatment of choice for CQ resistant P. vivax. WHO-recommended ACTs 
include artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and 
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dihydroartemisinin-piperaquine. Artemisinin in combination with effective partner 
drug have shown excellent cure rates in P. vivax infection [47]. ACTs with partner 
drugs with longer elimination periods provide incidental suppressive prophylaxis 
against relapse for about a month, but relapse risk thereafter remains relatively high.  
1.5.1.2 Treatment of severe vivax malaria 
Severe and fatal vivax malaria has been reported from Indonesia, Papua New Guinea, 
India, and Brazil [48]. The main manifestations are anemia and respiratory distress, 
although series of patients with coma, shock, and renal and hepatic dysfunction 
associated with vivax malaria have also been described. Plasmodium vivax is very 
sensitive to artemisinin and its derivatives. In the absence of comparative drug trials, 
physicians have tended to adopt a similar treatment approach for severe vivax malaria, 
namely administration of parenteral artesunate, if unavailable, artemether, and if that is 
also not available then quinine, along with broad spectrum antibiotic cover and 
supportive care. Intravenous artesunate also leads to a rapid clinical response in patients 
with severe vivax malaria, but there have been no randomized clinical trials in severe 
P. vivax malaria. Specific antimalarial treatment recommended in severe vivax malaria 
includes the following in order of preference:  
- Artesunate: 2.4 mg/kg body weight, intravenously or intramuscularly given on 
admission (time = 0), then at 12 and 24 hours, and then once a day. This is the 
treatment of choice.  
- Artemether: 3.2 mg/kg body weight, intramuscularly given on admission, then 
1.6 mg/kg body weight per day.  
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- Quinine: 20 mg quinine salt/kg body weight on admission (intravenous 
infusion in 5% dextrose/dextrose saline over a period of 4 hours) followed by 
maintenance dose of 10 mg/kg body weight 8 hourly (maximum infusion rate 
5 mg salt/kg/hour).  
Parenteral antimalarials should be administered for at least 24 hours. Once the patient 
can accept oral therapy, full course of oral ACT should be given to the patients. 
1.5.2 Treatment of liver stages of P. vivax 
Six 8-aminoquinolines have been used as antimalarial agents in humans [49]. Although 
most are no longer in use, all were evaluated first in animals and then in humans to 
assess their efficacy and toxicity in the treatment of malaria. All the 8-aminoquinolines 
that have been studied in detail are rapidly metabolized in humans in vivo, with only a 
small fraction (< 1%) eliminated unchanged in the urine. The commonest side-effect of 
these drugs is abdominal pain; the discomfort is proportional to the dose taken but is 
reduced (even at higher doses) when the drug is administered with food. The main 
concern throughout the development and use of 8-aminoquinolines has been the risk 
for haemolysis of G6PD-deficient individuals [50]. Pamaquine has pre-erythrocytic, 
radical curative and gametocytocidal properties. It has weak but significant activity 
against asexual stages of P. vivax and P. malariae but is ineffective against P. 
falciparum trophozoites. It was less effective in terms of radical curative activity than 
primaquine and was more toxic. Pentaquine was an effective hypnozoiticidal drug, but 
side-effects similar to those of pamaquine were observed frequently in carefully 
controlled studies, and its development was not continued. War in the Pacific in 1941 
created an urgent strategic need in the United States for a drug to prevent relapse of 
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malaria. Studies during and after World War II focused on 8-aminoquinolines, because, 
in the 1920s, pamaquine (the prototypical 8-aminoquinoline) had proven effective but 
too toxic. Primaquine became available to American troops during the Korean War 
[49]. 
1.5.2.1 Primaquine 
For over 60 years, clinicians, policy makers, and patients have relied on primaquine for 
the radical cure of P. vivax [51]. Primaquine is the only licensed antimalarial with 
proven hypnozoitocidal activity, but can result in significant hemolysis, particularly in 
those with glucose-6-phosphate dehydrogenase deficiency (G6PDd). Primaquine is 
indicated for radical cure of P. vivax or P. ovale malaria; for presumptive anti-relapse 
therapy (terminal prophylaxis) in people extensively exposed to P. vivax or P. ovale; to 
reduce onward transmission of P. falciparum malaria in programme to eliminate P. 
falciparum malaria and in areas threatened by resistance of P. falciparum to artemisinin 
[45].  
1.5.2.1.1 Structure and mechanism of action 
Primaquine is an 8-aminoquinoline, which is highly active against the exoerythrocytic 
forms (hypnozoites) and the sexual stages of malaria parasites (gametocytes). It has 
weak activity against the asexual blood stages of P. vivax and has negligible activity 
against P. falciparum. The precise mechanism of action of primaquine is not fully 
understood [52]. Several possible modes of action have been proposed. One hypothesis 
is that the active metabolite impairs the mitochondrial metabolism of parasites, 
interfering with the function of ubiquinone as an electron carrier in the respiratory chain 
[53]. Another theory is that the highly reactive metabolites generate intracellular 
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reactive species, which cause oxidative damage [54]. There is no evidence for acquired 
resistance to its hypnozoitocidal or gametocytocidal activities [55, 56]. 
1.5.2.1.2 Pharmacokinetics 
Primaquine is rapidly absorbed from the gastrointestinal tract, reaching peak 
concentrations within 1–4 h, with a bioavailability of about 96% [57]. Primaquine is 
biotransformed by two main routes: by monoamine oxidase (MAO) to the predominant, 
but inactive, metabolite carboxyprimaquine, which is relatively slowly eliminated; and 
via cytochrome P450 (CYP2C19, CYP2D6 and CYP3A4) in the liver, which generate 
the reactive intermediates responsible for antimalarial effects and haemolytic toxicity 
[58]. Genetic polymorphisms that decrease CYP2D6 enzyme activity reduce 
bioactivation of primaquine and may result in treatment failure. Primaquine is 
extensively distributed in the body. About 75% of primaquine in plasma is bound to 
proteins, and high concentrations occur in erythrocytes [45]. Primaquine crosses the 
placenta, but the concentrations of primaquine in breast milk are very low [59]. Because 
of lack of the data on its safety of haemolysis in a G6PD-deficient fetus or in infants < 
6 months, primaquine is not advised in pregnant and child-bearing women. Both 
primaquine and carboxyprimaquine are excreted mainly through the biliary tract and 
can be found in faeces within 24 h of administration [60]. Primaquine is also excreted 
in the urine as unchanged drug. The pharmacokinetics of a single oral dose of 15 mg 
did not appear to be altered in patients with severely impaired renal function and end-
stage renal dysfunction [61].  
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1.5.2.1.3 Antimalarial action 
Primaquine is active against pre-erythrocytic (liver) stages of all the parasites, the 
asexual and sexual stages of P. vivax, ovale, malariae and knowlesi, and the sexual 
stages of P. falciparum but is only very weakly active against the asexual blood stages 
of P. falciparum [49]. Primaquine is the only currently available antimalarial agent that 
kills the latent persistent stages of P. vivax and P. ovale (hypnozoites) in the liver [62]. 
As primaquine accelerates gametocyte clearance and reduces transmissibility, it is also 
used as a gametocytocidal drug against P. falciparum malaria [45]. 
1.5.2.1.3.1 Prevention relapse of vivax malaria 
It is difficult to evaluate the efficacy of any antimalarial agent in preventing vivax 
relapse, as in endemic areas relapses cannot be distinguished reliably from re-
infections. Relapse rates vary considerably by area, as do relapse intervals [15]. 
P. vivax infections relapse as a result of activation of persistent liver stages, 
hypnozoites. The incidence of relapses and the intervals between them depend on 
several factors, including the parasite strain (geographical origin), the size of the 
sporozoite inoculum and the immunity and age of the human host [9]. Three general 
patterns of infection can be distinguished: tropical (P. vivax Chesson strain), with 
frequent relapses at approximately 3-week intervals after administration of a rapidly 
eliminated antimalarial agent; temperate (Saint Elizabeth or Madagascar strain), in 
which a primary infection is usually followed by an interval of 8–9 months before 
relapse; and long or “hibernans”, in which there is no primary infection and the first 
illness occurs 8–9 months after sporozoite inoculation [9].  
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The dose of primaquine recommended globally was chosen largely on the basis of 
studies on the sensitive Korean P. vivax [63]. After a very high rate of relapse was 
observed in soldiers returning to the USA from the Korean War in 1950, all soldiers 
were given a radical curative regimen of 15 mg/day for 2 weeks during their return by 
sea, which was highly effective. The P. vivax Chesson strain from New Guinea was 
found to be more “resistant” to 8-aminoquinolines [64], but the recommendation for 
use of a higher primaquine dose (22.5 mg/day) was applied initially only in Oceania, 
although it might have been better to recommend higher doses for all areas in which 
frequent relapse parasites were found, including South-East Asia. It is possible that all 
“temperate strains” are equally sensitive to primaquine and that all “tropical strains” 
are equivalent but have higher “activatable” hypnozoite burdens and so require a higher 
dose (i.e. 0.5 mg/kg for 14 days) [62]. 
Most P. vivax endemic countries recommend a primaquine dosing regimen of 0.25 mg 
base/kg/day for 14 days, although there is a wide range of dosing regimens across 
countries [45]. The main problems with the standard 14-day course of 15 mg/day of 
primaquine following chloroquine are: poor adherence, since people become rapidly 
asymptomatic after treatment with chloroquine and are poorly motivated to complete 
primaquine treatment [65]; the risk of adverse events; the lack of availability of cheap, 
rapid and practical tests for G6PD deficiency. The efficacy of various regimens has 
been evaluated in different studies. Recurrence rates after primaquine (15 mg base/day 
for 14 days) were 4.6% at 3 months [66] and 17.5% at 6 months [67] in Thailand. 
Studies with similar primaquine doses reported a recurrence rate of 0% at 3 months 
(Thailand) [68], and 8.1% at 6 months (compared to 16.4% without primaquine (India)) 
[69], and 13.6% (Peru) [70] with chloroquine as the partner drug. In some areas of 
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South East Asia and Oceania, high-dose primaquine (0.5 mg base/kg/day for 14 days) 
is used. With this high dose course, the recurrence rates decreased by less than 5% in 
Thailand [71], by 3.5% in Vietnam [72]. In Papua New Guinea, this regimen reduced 
the risk of recurrence by 28% [73]. One study evaluated high dose primaquine in 
combination with chloroquine showed that  the recurrence rate was 1.8% over 
11 months  [74].  
1.5.2.1.3.2 Adverse effects 
While primaquine is generally well tolerated, it may cause dose-related gastrointestinal 
discomfort, including abdominal pain, nausea and vomiting [75]. This often happens in 
dose over 1 mg base/kg. Administration with food greatly improves tolerability [50]. 
Hypertension and cardiac arrhythmia have been reported rarely. The most important 
adverse effect is haemolysis in patients with glucose-6-phosphate dehydrogenase 
(G6PD) deficiency, and the degree of haemolysis is proportional to the dose, duration 
of exposure, and degree of G6PD deficiency [76]. Leukopenia, methaemoglobinaemia 
with cyanosis and granulocytopenia may also occur [76].  
1.5.2.2 Tafenoquine 
Tafenoquine, also known as WR238605, is an investigational 8-aminoquinoline 
derivative. Tafenoquine was first discovered at the Walter Reed Army Institute of 
Research in 1978, and jointly developed by Medicines for Malaria Venture (MMV) and 
GlaxoSmithKline Pharmaceuticals (GSK). Like primaquine, tafenoquine has activity 
against the hypnozoite of P. vivax lifecycle. Nevertheless, it has a long elimination half-
life (about 2-3 weeks) [77]. This novel drug is co-administered as a single dose with 
standard doses of chloroquine for the radical cure of P. vivax malaria [78]. This may be 
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a promising alternative to primaquine and an important practical advantage in order to 
increase the patient’s adherence [79, 80]. The shorter treatment course is an important 
practical advantage in people who do not have G6PD deficiency. However, the key 
safety issue for both primaquine and tafenoquine is the capacity to induce haemolysis 
in G6PD deficient patients [81]. Particularly, tafenoquine could cause sustained toxicity 
because of its slow elimination.   
1.5.2.2.1 Structure and mechanism of action 
Tafenoquine (TQ) is a prodrug that needs activation to quinone TQ metabolite through 
metabolism by CYP2D6 [82]. The mechanism of action of TQ is not yet precisely 
known. The spontaneous oxidation of metabolites also generates hydrogen peroxide 
and hydroxyl radicals. It is hypothesized that the reactive oxygen species generated 
through P. falciparum ferredoxin-NADP+ reductase and diflavin reductase enzymes 
leads to parasite kill. Similar to the blood schizonticide CQ, TQ inhibits heme 
polymerase in blood stage of the parasites [83].This may explain the reason why TQ 
has activity against asexual blood stage of parasites, unlike PQ that does not inhibit the 
polymerization of hematin. 
1.5.2.2.2 Pharmacokinetics 
The time to peak concentration of TQ is 13.8 hours. This could be due to a combination 
of prolonged absorption at distal gastrointestinal tract and the drug’s slow clearance 
[84]. Bioavailability of TQ increases when the drug is taken with high-fat meal [85]. 
From a population kinetics study of TQ in Thai soldiers, it was demonstrated that food 
affects the amount of TQ absorbed, rather than the rate of absorption [86]. The 
concentration of TQ in whole blood is approximately twofold higher than the 
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corresponding concentration in plasma. Like PQ, the activation of TQ needs 
metabolism by cytochrome P450 2D6 (CYP2D6) liver microsomal enzyme [87].  
1.5.2.2.3 Efficacy in radical cure 
Different doses of Tafenoquine were evaluated in clinical trials to find out the 
efficacious formula. High quality evidence on the efficacy of TQ for radical cure is 
obtained from double-blind, multicenter, randomized, placebo-controlled Phase IIb 
study [88]. Single dose of TQ at 300 mg and 600 mg, following the standard CQ therapy 
for clinical cure, prevented relapse of vivax malaria by 91.9% and 96.5%, whereas 15 
mg PQ administered for 14 days prevented relapse only by 77.3%. In a meta-analysis, 
a lower efficacy of single dose of 300 mg TQ has been shown by preventing 74% of 
participants free from recurrence after 6 months of follow-up in Southeast Asian region 
[89]. Tafenoquine has good efficacy in preventing relapses up to six months by clearing 
vivax hypnozoites when used at a total dose of 300 mg or more, raising the possibility 
of single-dose treatment and directly observed therapy [90].  
1.5.2.2.4 Safety of Tafenoquine 
Like other 8-aminoquinoline, the most frequent complaint of tafenoquine is 
gastrointestinal abnormalities (nausea and abdominal pain) [91]. Mild vortex 
keratopathy, corneal deposits were also detected in 93% of subjects taking tafenoquine. 
These disorders were not associated with any effect on visual acuity and were fully 
resolved in all subjects by 1 year [92]. There is no evidence of a relationship between 
tafenoquine dosage and the occurrence of abnormal laboratory parameters, including 
aminotransferase, hemoglobin, white blood cell counts, platelets and bilibrubin levels 
[93]. Major complication with tafenoquine administration is the acute haemolysis in 
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G6PD deficient subjects [94]. Prolongation of the QT interval is also one of the 
concerns in patients treated with antimalarial drugs. In the DETECTIVE trial, QT 
prolongation occurred in 2% of patients taking tafenoquine, while the phenomenon was 
observed in 8% and 4% of patients taking primaquine and chloroquine, respectively 
[88]. 
1.6 Glucose-6-Phosphate Dehydrogenase Deficiency and Radical cure of 
Plasmodium vivax 
1.6.1 Epidemiology of Glucose-6-Phosphate Dehydrogenase Deficiency  
The presence of G6PDd in patients with P. vivax infection results in significant 
challenges to achieving radical cure. G6PDd is the most common enzymopathy with at 
least 400 million individuals affected worldwide [95]. G6PD deficiency is widespread 
across malaria endemic regions. At the continental scale, the high allele frequencies 
seen in Africa meant that 28.0% of the overall deficient population was in sub-Saharan 
Africa, while only 4.5% of the global population burden was in the Americas, and 
67.5% across the whole of Asia [96]. The prevalence of G6PD deficiency and 
predominant G6PD deficiency variants can vary by ethnicity [97]. In Asia, the 
prevalence of G6PD deficiency is as high as 20%, while in Americas and Africa, this 
number can vary from < 1% to 15% [96, 98, 99]. More than 185 clinically relevant 
variants of G6PDd have been reported with a spectrum of associated enzyme 
deficiencies. In Asian populations, different variants have been identified, such as the 
Mahidol variant across Myanmar and Thailand; Viangchan variant across Mekong 
region; Kaiping variant among Chinese populations and the Vanua Lava variant in 
central and eastern Indonesia, genetic diversity was high among these populations. The 
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proportion of “unidentified” variants was also greatest among Asian populations, 
emphasizing the inadequacy of molecular methods for diagnosing phenotypic 
deficiency: a limited number of primers cannot reliably identify all possible cases of 
deficiency [96]. The high prevalence of these mutants is likely to have been driven by 
their ability to provide some degree of protection from malaria. 
1.6.2 Physiology of Glucose-6-Phosphate Dehydrogenase Deficiency 
Gucose-6-phosphate dehydrogenase is an essential enzyme in the pentose phosphate 
pathway (PPP), the only pathway for human RBC to maintain the cells’ redox potential 
by reducing NADP+ to NADPH. The enzyme consists of two dimers encoded by a gene 
on the long arm of the X chromosome. Non-synonymous mutations in the gene can 
decrease enzyme activity or reduce the stability of the enzyme, resulting in different 
degrees of G6PD deficiency. Because the gene is on the X chromosome, males are 
hemizygous and are either classified as G6PD deficient or normal by phenotype. 
Females have two gene copies which are expressed alternately in RBCs. Females 
therefore can be homozygous deficient (two gene copies with a deleterious mutation), 
heterozygous with one gene copy encoding a normal G6PD variant and one gene copy 
encoding a deficient G6PD variant (and a phenotype ranging from normal to deficient), 
or homozygous normal with both gene copies expressing G6PD variants with normal 
G6PD activity. Through the process of X-chromosome inactivation (also called 
Lyonization), females express only one of their two copies of the gene in each cell. This 
occurs randomly in the precursors of RBCs early in the embryonic stage and results in 
different ratios of gene expression in mature RBCs amongst females but is constant 
within an individual [100]. As consequence females heterozygous for G6PD can 
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manifest a range of intermediate G6PD activities between typical normal and deficient 
G6PD activities that reflects the average enzymatic activity of these two cellular 
populations. 
1.6.3 Clinical features of Glucose-6-Phosphate Dehydrogenase Deficiency 
Most people with G6PDd do not exhibit symptoms unless exposed to oxidative stress. 
Oxidative stress can be triggered by medicines, infections, fava bean consumption, or 
even strenuous physical exercise [101]. The main clinical manifestations of G6PDd are 
acute haemolytic anaemia, chronic non-spherocytic haemolytic anaemia (CNSHA), 
neonatal jaundice and favism [102, 103]. The World Health Organization (WHO) 
classifies G6PDd into five different categories according to the severity of enzyme 
deficiency. A Class I deficiency is defined as severe deficiency and is associated with 
CNSHA. A Class II deficiency is also defined as severe deficiency and the enzyme 
activity is 1%-10% of normal activity. Individuals with a Class III deficiency are 
moderately deficient and their enzyme activity is 10%-60% of normal activity. Class 
IV and Class V individuals have normal and increased activity with an enzyme activity 
of 60%-150% and over 150%, respectively [102]. The two most common G6PDd 
variants are the G6PD A- and G6PD Mediterranean variants. G6PD A- is common 
across the African continent and is categorized as a Class III deficiency, whereas G6PD 
Mediterranean is common among Italians, Arabs, Persians, and Jews, and is categorized 
as a Class II deficiency. In Southeast Asia, the most common variant in Myanmar and 
Thailand is G6PD Mahidol (Class III), whereas in Laos and Cambodia, the most 
common variant is G6PD Viangchan (Class II) [95]. 
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1.6.4 Diagnosis of Glucose-6-Phosphate Dehydrogenase Deficiency 
In the Great Mekong Subregion (GMS), many malaria endemic villages are remote, 
difficult to access and have very weak health infrastructures [104]. Therefore, when 
haemolysis occurs in such settings, the local health facilities are unlikely to be able to 
provide appropriate medical care, potentially resulting in the loss of life. G6PD testing 
is particularly crucial under such conditions. Implementing routine testing for G6PD 
deficiency is challenging and the WHO guidelines also state that if testing is not 
available, an individual risk-benefit assessment should guide the decision whether to 
administer without testing or withhold radical treatment altogether [105]. G6PD testing 
is currently available in a number of formats. Diagnostic assays can be grouped into 
genotypic test assays, sequencing methods as well as phenotypic assays [106]. 
Genotypic assays and sequencing methods can provide a precise option for diagnosing 
G6PD mutations but require long and complicated test procedures, a well-equipped 
laboratory and high trained staff. Phenotypic tests can be grouped into qualitative, 
quantitative and cytochemical test assays. Phenotypic tests are based on the direct or 
indirect detection of NADPH + H+, formed as a result of G6PD activity [107]. 
Qualitative test formats indicate activity above a test’s inherent activity threshold level. 
While qualitative test formats are easier to perform and interpret compared to 
quantitative test methods and cytochemical tests, the reduction of a quantitative value 
(G6PD activity) to a binomial outcome poses difficulty in differentiate the females with 
heterozygous G6PD alleles because of technical reasons. A quantitative test assays will 
accommodate different threshold activities and within limits is able to identify 
heterozygous females as individuals with intermediate G6PD activity. Most 
quantitative test assays to date require a good laboratory infrastructure and well-trained 
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staff. Handheld devices that do not rely on laboratory and can provide results within 
several minutes are currently being introduced. 
Only cytochemical assays can effectively distinguish between G6PD normal and G6PD 
deficient RBCs on a cellular level and can effectively identify heterozygous women 
with a high percentage of G6PDd red blood cells that are accordingly at risk for severe 
haemolysis [108, 109]. There are flow cytometry-based assays that allow the 
measurement of G6PD activity in labelled RBCs. The main drawbacks of this format 
are the complexity of the respective test assays and interpretation, the need for costly 
machinery and the long turn-around time that make these assays unsuitable for PoC 
testing [110].  
The gold standard test is by spectrophometry and flow cytometry. Although these tests 
quantify enzyme activity, they are expensive and require a well-functioning laboratory 
infrastructure. However, in the setting of the impoverished rural tropics, the 
requirements for laboratory skills, refrigeration, specialized equipment, and high costs 
have excluded its availability to the vast majority of patients suffering malaria. A 
number of qualitative tests have been introduced over the last couple of years with 
superior operational characteristics and comparable diagnostic performance. Since 
1979, the fluorescent spot test (FST) is recommended as the most suitable method for 
screening in the field [111]. However, the FST is not suitable for remote locations 
without laboratory facilities and requires experience in its interpretation. Expert 
consensus defined practicality criteria for point-of-care (PoC) G6PD diagnostics that 
included simplicity of use, ease of interpretation, no specialized of equipment or cold 
chain, and relatively low cost. Expert consensus also acknowledged that the availability 
of such robust devices where most malaria patients live is a key to the control and 
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elimination of endemic P. vivax malaria [106, 112]. In recent years, novel technologies 
are changing the landscape and three new PoC devices have been implemented. Two 
companies, Accessbio (New Jersey, USA) and Alere (Maine, USA), have developed 
different types of PoC diagnostics for G6PD deficiency that focus on rapid diagnosis, 
with limited need for technical training and infrastructure. The format of the qualitative, 
lateral flow RDT is similar to many malaria RDTs on the market. The G6PD RDT is 
based on the reduction of colourless nitro blue tetrazolium dye to dark coloured 
formazan [113]. The appearance of a purple/blue coloration indicates a G6PD normal 
result. While the BinaxNOW G6PD test (Alere, USA), available since 2008, has good 
performance in controlled laboratory settings, performance of this test in less controlled 
settings was less satisfactory [114]. BinaxNOW presents a major drawback with the 
need to perform the test within a temperature ranging from 18 to 25°C, imposing limited 
usefulness in tropical malaria-endemic countries [115]. In 2013, Accessbio (USA) 
released the CareStart G6PD test onto the market. The assessment of the CareStart 
G6PD revealed performance characteristics essentially similar to the current screening 
standard, the FST [116]. However, the current CareStart does not include a control-line, 
a short-coming that affects result validity.  
The degree of G6PD activity can help to guide clinical management, but the relevant 
threshold varies with the intended use. All of these tests have a threshold of around 30% 
enzyme activity, a threshold sufficient to discriminate G6PDd homozygous females and 
hemizygous males, from G6PD normal but inadequate for heterozygous females, with 
intermediate enzyme activities above 30% of normal but below a pre-defined 
considered safe threshold such as 70% from normal. The threshold of current qualitative 
Point-of-care tests is considered sufficient to guide PQ treatment, however 
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heterozygous females are at substantial risk of drug induced haemolysis and there are 
concerns regarding the safety of prescribing the long acting TQ in patients with enzyme 
activity of less than 70% [117]. Diagnosis of this higher threshold will require more 
discriminative quantitative tests. Biosensors, the second type of PoC device developed, 
are handheld devices that in conjunction with a disposal strip provide a quantitative 
result. These tests directly measure G6PD activity from collected blood based on 
electro-chemical properties of the sample. In 2015, AccessBio (USA) launched the 
CareStart Biosensor, which at present, is the only product of this type on the market.  
Several factors can influence the performance of a G6PD test and its ability to correctly 
classify a patient as either normal or deficient, starting with the cut-off definition. These 
include biological conditions such as concomitant haemoglobinopathies, recent 
haemolysis events that leave a patient with a relatively high proportion of young cells 
with high G6PD activity that can produce a false normal result, and high leukocyte 
counts that also lead to a false normal G6PD result [112]. Because they are enzyme 
activity tests, the G6PD assays are particularly sensitive to specimen handling and 
reaction conditions.  
The evaluation of a novel quantitative assay requires comparison with an appropriate 
quantitative reference method. Additional tests such as genotyping and flow cytometry 
provide complementary information on underlying G6PD variants and heterozygosity. 
Several quantitative assays have emerged that either directly or indirectly measure 
NADPH formation as a result of G6PD activity, however the majority of test 
evaluations have used spectrophotometry as a reference method. Absolute values can 
vary between different essays and hence results need to be transformed into population 
specific values relative to the population specific adjusted male median. Presentation 
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of the results without the corresponding adjusted male median (AMM) value 
significantly confounds the comparison of the essay results across different studies.  
The G6PD activity is defined as one International Unit (U) is the amount of G6PD 
activity that will convert 1 micromole of NADP+ per minute under predetermined 
substrate and reaction conditions. Activity may be expressed in either a standard 
number of cells (U/1012 RBCs) or amount of Hemoglobin (U/g Hb) [102]. Typically, 
G6PD activity in a population is bimodal, with a minor group of individuals clustered 
around 10% or less G6PD activity and most clustered in the 60% to 150% range.  
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Chapter 2 
The Clinical Manifestations of Plasmodium vivax malaria in Vietnam  
2.1 Introduction 
Plasmodium vivax malaria is a significant public health issue in many parts of the world. 
In 2015, P. vivax is estimated to have been responsible for 13.8 million malaria cases 
globally, and accounted for approximately half the total number of malaria cases 
outside Africa. Most cases of P. vivax malaria occur in the WHO South-East Asia 
Region (74%) [118]. Clinical diagnosis of vivax malaria is difficult because signs and 
symptoms are non-specific and impacted by endemicity and host immunicity. Common 
symptoms include fever, malaise, chills, diaphoresis, headache, arthralgia, myalgia, 
cough, abdominal pain, nausea, vomiting, and diarrhea, which can also occur with many 
common systemic febrile illnesses such as meningitis, pneumonia or gastroenteritis. 
Splenomegaly, anemia, leucopenia and thrombocytopenia are also common, but non-
specific [24]. The spectrum of disease associated with P. vivax infection ranges from 
asymptomatic parasitaemia and uncomplicated febrile illness through to severe and 
fatal malaria. Vivax malaria was historically described as benign and self-limiting 
infection because individual clinical episodes were less likely to cause severe illness 
than Plasmodium falciparum. More recently, P. vivax has been shown to cause severe 
anemia, respiratory failure, malnutrition, and possibly coma [119]. In malaria 
elimination era, with the successful in controlling P. falciparum, the incidence of vivax 
cases has decreased more slowly than that of the falciparum because of key differences 
in parasite and vector biology [120]. Vivax becomes predominate and persists as the 
principal cause of malaria. Since the 1990s, the malaria burden in Vietnam has been 
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efficiently reduced (> 90%) by the national control program and malaria is now 
confined to the remote and forest areas populated mainly by poor ethnic minorities 
[121]. In 2015, there were totally over 19,000 malaria cases in Vietnam, in which P. 
vivax accounted for 51% [122]. For that reason, P. vivax becomes an important problem 
in malaria control programme. Although there are studies related to P. vivax, most of 
them described the other fields outside the clinical manifestations, we conduct a study 
to describe the clinical and laboratory signs and symptoms of an episode of acute vivax 
malaria in Vietnam in order to have an accurate and appropriate diagnosis as well as a 
correct treatment.  
2.2 Methodology 
2.2.1 Study sites 
The descriptive longitudinal study was a part of two clinical trials 1) to evaluate the 
safety and efficacy of short course of primaquine and 2) to assess the haemolysis risk 
of single dose tafenoquine (Chapter 3 and 4). This study was carried out in patients with 
P. vivax malaria in the health facilities of Bu Gia Map district, Binh Phuoc province 
and Krong Pa district, Gia Lai province from October 2014. Binh Phuoc and Gia Lai 
Province are the remote areas that have the highest incidence of malaria cases out of 
the country. Binh Phuoc Province is located 200 km North West of Ho Chi Minh city. 
It consists of about 932,000 people belonging mainly Kinh and S’tieng ethnic group. A 
minor part of the population is Tay and Nung people who are immigrants from the 
Northern provinces. The habitations of local people are surrounded by cashew nut or 
coffee tree gardens. Gia Lai Province is located in the central of Vietnam, the 
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mountainous region. It has many communes living nearby forest and mountain. The 
habitants are about 1.36 million people with mainly the J’rai ethnic group.  
Sample size: The sample size of this descriptive study was calculated based on 
the following equation  
𝑛 ≥  (
1.96
𝑚
)
2
 ?̂?(1 −  ?̂?) 
 
m: sampling error = 0,05 
p: proportion of P. vivax malaria presenting a specific symptom or sign = 0.5 
Z = confidence level = 1.96 with a two-sided significance level of 5%, and a 
power of 80% 
n = sample size = 385 participants 
2.2.2 Study procedures 
All of the patients were included in the study as they attended to at the malaria diagnosis 
facilities; men and women were selected according to the criteria.  
- Inclusion criteria: All the following had fulfilled: a. > 6 months of age; b. > 5 
kg of weigh; c. Mono P. vivax infection; d. Fever (axillary temperature  37.50C) or 
history of fever in the last 48 hours; e. Informed consent (signed by the patient or his/her 
parents if underage). 
- Exclusion criteria: To have at least one of the following: a. Pregnant or lactating 
female; b. Inability to tolerate oral treatment; c. Severe/Complicated malaria; d. Hb < 9 
g/dL; d. Another conditions affect the results of the study (serious underlying cardiac, 
renal or hepatic disease, severe malnutrition, HIV, severe febrile condition other than 
malaria). 
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Malaria diagnosis: Diagnosis, species and number of parasites were determined by 
Giemsa stained thick and thin blood smears. 
Clinical evaluation: After the diagnosis, anamnesis and clinical evaluation were done 
and by a physician. A case sheet proforma was prepared and the data (demographic 
profile, clinical features, investigation, treatment and complications) from all the case 
records were filled up and later on were analyzed.  
Laboratory tests: At the enrollment in the study, capillary blood sample was obtained 
for the following tests: Field Blood Haemoglobin, parasite microscopy. Microscopy 
will be used to confirm the presence of parasitaemia and to estimate the parasite density. 
Standard thick (6 µL blood on a 12-mm diameter template) and thin malaria films were 
stained with Giemsa (3% in 40-50 min). Blood films were considered negative if no 
parasites were detected after examining 200 high-power fields (magnification x 1000) 
on the thick film. Parasite counts were obtained from thick or thin films by counting 
the number of asexual parasites on a minimum of 40 high-power fields on the thick film 
or by assuming 5 x 106 erythrocytes per µL for thin film counts. A venous blood sample 
was also obtained for the Complete Blood Count if available. 
Treatment: All of the participants will be treated with a 3-day regimen of chloroquine 
with the total dosage of 25 mg base/kg [105]. Parasite blood smears will be examined 
every day until 2 consecutive smears are negative.  
2.2.3 Statistical analysis 
All analyses were performed with the statistical software R3.3.1 (R Foundation for 
Statistical Computing, Vienna, Austria). Frequencies of various symptoms and signs 
were determined. Age and laboratory alterations were calculated by Median + Range.  
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2.2.4 Results 
2.2.4.1 Patient characteristics 
From October 2014 up to November 2017, a total of 389 cases with P. vivax diagnosis 
were admitted to the study, of which 326 (84%) were males and 63 (16%) were females. 
The number of admissions due to malaria fluctuated during the study period, and 
reached the highest in the end of 2015 and the beginning of 2016 (Fig.2.1). 345 
(88.76%) patients carried out works related with agriculture. The minority ethnic was 
accounted for three fourth of malaria cases. The median age is 24 years old with the 
range between 4 and 68 years old. Twenty-seven of 389 (6.9%) patients were children 
less than 15 years of age. The age distribution of patients is shown in Fig.2.2.   
 
Figure 2.1: Seasonal malaria incidence pattern 
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Figure 2.2: Age distribution of study population 
2.2.4.2 Symptoms and physical findings 
Signs and symptoms analysis on admission is shown in Table 2.1. The evolution time 
of the disease from the start of the symptoms to the moment of clinical evaluation was 
from 0 to 21 days and the mean of nearly 2 days. Headache were reported in 203 
(68.81%) cases, chill in 45 (15.25%) cases and heavy sweating in 32 (10.85%) cases. 
Other symptoms only presented in small percentage like diarrhea, abdominal pain and 
insomnia.  
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Table 2.1: Symptoms and clinical signs at admission 
 On general physical examination at admission, 389 (100%) cases had the temperature 
higher than 37.50C. The median temperature of the patients was 38.70C, of which half 
of the cases (51.35%) had the temperature above 390C. Jaundice and hepatomegaly 
were recorded in only 3 cases and 1 case, respectively. Two cases with spleen 
enlargement were described. 
2.2.4.3 Laboratory abnormalities 
Laboratory abnormalities are shown in Table 2.2 and 2.3. The median of haemoglobin 
concentration was 13.5 g/dL with range from 9.3 to 16.8 g/dL. Anaemia was observed 
in 112 (28.81%) patients based on age-adjusted reference value [123]. Of 143 patients 
whose blood samples were tested for full blood count, thrombocytopenia was common 
(82.4%) although in most cases it was mild-to-moderate (50,000 to 150,000 
 Number of patients % 
Symptoms    
Fever  389 100 
Headache  203 52.2 
Chill/Rigor  45 11.6 
Heavy sweating  32 8.2 
Anorexia  31 8.2 
Fatigue  29 7.5 
Nausea  19 4.9 
Dizziness  17 4.4 
Muscle pain  12 3.1 
Vomiting 11 2.8 
Coughing  11 2.8 
Diarrhea  5 1.3 
Abdominal pain  3 0.8 
Insomnia  3 0.8 
Signs    
Jaundice  3 0.8 
Hepatomegaly  1 0.3 
Splenomegaly 2 0.5 
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platelets/L); only 9 patients (6.7%) had low platelets levels (25,000 to 50,000 
platelets/L) without clinical bleeding manifestations. Leukopenia (WBC < 4,000/L) 
was present in 10 (6.99%) patients.  
Table 2.2: Sex and age hemoglobin values (g/dL)  
Age No. 
Hemoglobin 
X ± SD 
Anemia 
No. (%) 
Reference value 
(lower value) 
6m - < 5 y 1 10.4 1 (100) 11.0 
5 – 11  22 11.55 ± 1.2 9 (52.94) 11.5 
12 – 14  18 12.58 ± 0.89 2 (22.22) 12.0 
>15 (women) 53 12.54 ± 1.38 16 (40) 12.0 
>15 (men) 295 13.82 ± 1.35 57 (25) 13.0 
 
Table 2.3: Hematological values in 143 patients 
Laboratory value  No. of patients (143) Percent of total  
White blood cells (/L)   
< 2,000 0 0 
2,001 – 4,000 10 6.99 
4,001 – 10,000  122 85.31 
10,000+ 11 7.7 
Platelets (/L)   
< 25,000 0 0 
25,001 – 50,000  9 6.29 
50,001 – 75,000 27 18.81 
75,001 – 150,000  82 57.34 
150,001+ 25 17.56 
2.2.4.4 Parasite densities 
The parasite densities ranged from 517 to 58,740 parasites per microliter of blood, and 
the median parasite density was 7,508. Approximately 60% (n=230) of subjects had 
asexual parasitaemia less than 20,000/µL at admission (Figure 2.3). Of the 389 patients, 
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292 (75.5%) cases had gametocytes on peripheral blood smears at the time of 
admission. 
 
Figure 2.3: Asexual parasitaemia distribution among participants 
2.2.4.5 Treatment response and complications 
In all the participants, fever resolved promptly after a standard course of chloroquine 
treatment. In our study, the clinical course of vivax malaria was usually benign. All of 
the patients recovered fully with no severe complications. The mean fever clearance 
time and parasite clearance time were 1.53 and 2.08 days, respectively. However, 5 
cases still had mild fever until Day 3 post treatment and 6 cases had positive parasite 
blood smear on Day 3.  
2.3 Discussion 
The study showed that the majority of the patients were males and 88% of them worked 
in agriculture-related work. Males were affected than females, which is possibly due to 
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increased outdoor activities and increased exposure to mosquitoes in males as compared 
to females. Information regarding age and gender related prevalence of malaria is scarce 
but most of the studies reported generally a high burden in males compared to females, 
our study also showed similar results [124, 125]. In areas where major epidemiological 
shifts toward elimination have occurred, the adult males were predominant in vivax 
patient population that will sustain transmission [126]. From this study, most of the 
participants presented with vivax infection during the rainy season. This may be caused 
by the favorable humid climate and warm stagnant water with aquatic vegetation for 
mosquito vector breeding, which is comparable with other study [127].  
The common signs, fever and headache, were present in nearly 100% of the patients. 
This is similar compared to other studies [128, 129] and also agrees with classic 
findings [119]. Infection of a non-immune host results in a prodromal period followed 
by an acute fever. The temperature rises before the rigor ceases, usually reaching a peak 
1 – 3 hours after the rigor finishes, commonly 39.5-40.50C but occasionally over 41.50C 
[24]. In our study, 51.35% of cases had the temperature above 390C.  In both adults and 
children, P. vivax has a lower pyrogenic threshold (the parasite density required to 
evoke a fever) compared to P. falciparum, which median parasitaemia in uncomplicated 
vivax malaria lower than that seen in uncomplicated falciparum malaria [24]. However, 
the parasite blood smears of the study participants had a median of 7,500 parasites/L, 
different from other studies [130, 131]. Headache, anorexia, vomiting, myalgias, 
abdominal pain and diarrhea commonly occur during the paroxysm of vivax malaria 
[24]. Respiratory symptoms have long been recognized as common in vivax malaria, 
but in our study, coughing was only recorded in 11 cases. The signs of vivax malaria 
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were not typical, usually jaundice, hepatomegaly or anaemia. Malaria is the most 
frequent cause of spontaneous splenic rupture, which occurs commonly in P. vivax 
parasite infection [132]. The spleen enlargement is a widely prevalent feature of 
malaria. However, the average enlargement of the spleen is considered to be greater in 
highly endemic malaria regions [133]. As the endemicity of malaria has decreased in 
Viet Nam, the occurrence of splenomegaly in participants was relatively low. The 
frequency of clinical signs was significantly lower than the frequency of symptoms, 
which confirms what is already well known. In comparison with P. falciparum malaria, 
fever was significantly less frequent in P. vivax cases, whereas pallor was more frequent 
in P. vivax infected patients. Uncommon symptoms, such as vomiting, cough, and 
diarrhea were mostly reported in P. vivax patients. Patients presented with 
hepatosplenomegaly all with P. vivax infections [134].  
Hematological changes, which are one of the most common complications, play an 
important role in increasing mortality. Anaemia is known to be associated with malaria 
in endemic areas, although malaria may not be the prime cause of it. The pathogenesis 
of anaemia in malaria is complex and multifactorial. It is often thought to result from a 
combination of hemolysis of parasitized red blood cells, accelerated removal of both 
parasitized and unparasitized red blood cells, depressed as well as ineffective 
erythropoiesis with dyserythropoietic changes, and anaemia of chronic disease. Other 
contributing factors may include decreased red blood cell deformability, splenic 
phagocytosis and/or pooling, leading to an increased rate of clearance from the 
circulation [135]. Anaemia was observed in 85 (28.81%) patients. The degree of 
anaemia in an individual is influenced by a wide range of factors including premorbid 
haemoglobin concentration, level of immunity, duration of infection before treatment, 
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the number of prior episodes of malaria, as well as the presence of comorbid conditions. 
Moreover, the anaemia status can be related with helminth infections and iron 
deficiency anaemia, especially in ethnic minority community [136]. Anaemia 
associated P. vivax infection is amongst the commonest manifestations of severe vivax 
disease and is more strongly skewed towards young children [24]. This percentage of 
anaemia is lower than other studies with 73% and 35.77% of the cases were anaemic, 
respectively [125, 137].  
Despite not being a criterion for severe malaria, thrombocytopenia is one of the most 
common complications of P. vivax malaria. Platelets count under 150,000/L occurs in 
24 – 94% of patients with vivax malaria [24, 135, 137-139]. Thrombocytopenia was 
the most frequent laboratory abnormality found in our study, presenting in 82.44%, but 
severe thrombocytopenia was not seen and clinical bleeding did not occur. Our finding 
is comparable to other studies [128, 137, 140, 141]. The speculated mechanisms leading 
to thrombocytopenia are: coagulation disturbances, splenomegaly, bone marrow 
alterations, antibody-mediated platelet destruction, oxidative stress [138]. This 
phenomenon improves with disease resolution and the platelet count is generally 
normal in one or two weeks [142]. However, the trend of disease with P. vivax malaria 
is changing. All complications seen in falciparum positive cases are being seen in vivax 
positive cases also. Thrombocytopenia may not be a cause of mortality by itself, but it 
can be a marker of increased severity and need of aggressive management [140]. The 
presence of thrombocytopenia in malaria patients is not a distinguishing feature 
between P. falciparum and P. vivax infection [142]. Furthermore, in tropical countries, 
malaria and dengue fever are prevalent and the challenge of making correct differential 
  
 
 
 
58 
 
diagnosis between two diseases may be difficult. Clinicians in the tropical areas should 
think of malaria and dengue whenever a patient present with acute febrile illness and or 
thrombocytopenia [143]. 
In this study, almost 75% of patients at the time of P. vivax infection diagnosis had 
gametocytes in their blood. This is similar to that found in other research [125, 129]. P. 
vivax gametocytes are present earlier in the progression of a primary or recrudescent 
infection than P. falciparum and mature faster, and may, therefore, be transmitted 
earlier in the course of infection before being diagnosed or treated [126, 144].  
Chloroquine is the first-line treatment for P. vivax malaria in most endemic countries, 
but chloroquine resistance was also recorded in many places, such as Indonesia and 
Oceania [145]. The standard chloroquine total dose of 25 mg base/kg is administered 
as three daily doses. This typically clears chloroquine-sensitive blood-stage P. vivax 
parasites within 48 hours [126]. In our study, there were 6 cases (2%) that had positive 
asexual parasite blood smear after 48 hours after chloroquine treatment and 5 mild fever 
cases on day 3. Clearance of parasitaemia (assessed by microscopy) in all patients by 
day 3, or in 95% of patients by day 2, was 100% predictive of chloroquine sensitivity 
in the study population as defined by day 28 recurrence [145]. In central of Vietnam, 
confirmed P. vivax chloroquine resistance was described for the first time in 2009 with 
optimal measured chloroquine blood concentration [125]. The mean fever clearance 
time and parasite clearance time of our study were 1.53 days and 2.08 days, respectively 
while other study showed more rapid fever clearance time and parasite clearance time 
[146]. In southern Vietnam, in another study, chloroquine has been proved efficacious 
for the treatment of P. vivax, but dihydroartemisinin-piperaquine provided more rapid 
symptomatic and parasitological recovery [146].  
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There were some limitations in this study. Firstly, all subjects were male which may 
have impacted findings. Secondly, one exclusion criterion of our study was if 
haemoglobin concentration was below 9 g/dL, which occurred in 9 patients. This 
exclusion of these anaemic subjects could underestimate the prevalence of severe 
anaemia of vivax patients in malaria endemic regions. Furthermore, this study did not 
investigate the biochemistry laboratory values, so that the clinical features of vivax 
patients are thus not fully described.  
This study focuses on clinical and laboratory findings in vivax malaria. Although these 
clinical and laboratory alterations in association with malaria are not new to the subject, 
this data adds more detailed information to the current knowledge in manifestation of 
vivax malaria.  
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Chapter 3 
Improving the radical cure of vivax malaria: A placebo-controlled 
comparison of short and long course of primaquine regimen 
 
3.1 Introduction 
In 2018, while Plasmodium falciparum is the most prevalent malaria parasite in the 
WHO African Region, 53% of the Plasmodium vivax malaria burden comes from the 
WHO South-East Asia Region [4, 147]. Historically, vivax malaria has been considered 
as a benign infection, there are now more evidence to prove it can cause death and 
severe cases [119, 148, 149]. The main distinct biological characteristic in the life cycle 
of P. vivax is the appearance of dormant liver stages, called hypnozoites. After the 
initial infection, the hypnozoites stay in the liver, then under certain circumstance they 
can be awakened and cause recurrent illnesses in the following weeks or months [9, 
150]. This stage in life cycle is refractory to most of antimalarial drugs and relapses is 
the main source of vivax malaria in endemic areas [73].  
Primaquine, an 8-aminoquinoline, has been used as the only drug that can kill 
hypnozoites, thus preventing relapses [49, 62, 151]. However, the coverage of this drug 
is limited due to the risk of acute haemolysis in patients with glucose -6-phosphate 
dehydrogenase deficiency (G6PDd) [50]. The efficacy of PQ depends on the total dose 
whereas the adverse reactions are mostly associated with the daily intake [151]. The 
World Health Organisation has recommended 0.5 mg/kg/day for 14 days of PQ in 
G6PD normal patients to prevent relapses in areas where frequent relapsing strains of 
P. vivax are prevelant [45]. However, the adherence of the prolonged treament in 
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malaria endemic settings is low. This can result in a significant reduction in PQ 
effectiveness [68, 152, 153]. Short courses with higher daily dose may improve the 
adherence and thus effectiveness without compromising efficacy [71, 154, 155]. The 
primary objective of this study was to assess the safety, tolerability and efficacy of a 7-
day high dose (1 mg/kg/day) PQ regimen for vivax malaria in patients screened as 
G6PD-normal. 
3.2 Methods  
3.2.1 Trial design 
This was a multi-site, randomised, double-blinded, placebo-controlled, non-inferiority 
trial in G6PD-normal patients with uncomplicated vivax malaria. There were 4 
countries participating this trial; including Indonesia, Ethiopia, Afghanistan and Viet 
Nam. Ethical and drug regulatory approvals were obtained from the Oxford Tropical 
Research Committee, the relevant national and local committees and authorities. The 
study protocol has been published previously [156]. The result from this multi-site trial 
has been published in The Lancet [157]. This chapter only described the results derived 
from Vietnam participants. From Viet Nam site, eligible patients presenting to Dak O 
and Bu Gia Map Commune Health Station in Binh Phuoc province and Krong Pa 
Medical Centre in Gia Lai province were screened to enroll into the study. Sharing as 
the role of site principal investigator, I had the oversight responsibility in conduct of 
the study. I supervised the study performance and ensured the participants’ well-being 
and safety were protected; all the study procedures were conducted at the research sites 
in accordance with the protocol and International Conference on Harmonisation – Good 
Clinical Practice (ICH-GCP).  
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3.2.2 Participants 
Patients presenting with uncomplicated vivax malaria (mono-infection) who had fever 
or history of fever within the last  48h, were aged > 6 months and weighed  5kg, 
haemoglobin concentration  9 g/dl, and normal G6PD status as assessed by the 
fluorescent spot test (FST) were eligible for enrolment. Patients were excluded if they 
were pregnant or lactating, could not tolerate oral treatment, had a history of previous 
haemolytic episodes or blood transfusion within the last 90 days, or had signs of severe 
malaria. Other exclusion criteria included any hypersensitivity to study drugs, or 
concomitant medication with the potential to cause haemolysis or interference with the 
pharmacokinetics of the study drugs.  
Before enrolment, written informed consent was obtained from the patient or their 
guardian as well as assent if aged 12 to 18 years. Patients with G6PDd were excluded 
from the main trial, but enrolled into a parallel observational arm and treated with 
chloroquine (CQ) plus supervised PQ (0.75 mg/kg) once a week for 8 weeks.  
3.2.3 Randomisation and masking 
Eligible patients were treated with a blood schizontocidal drug (Chloroquine in 
Vietnam) and assigned randomly in a 2:2:1 ratio to a 7-day PQ regimen (PQ7), a 14-
day regimen (PQ14) or placebo. The allocation ratio of 2:2:1 was based on the sample 
size requirements for the non-inferiority comparison of a 7-day primaquine regimen 
with a 14-day regimen, and the superiority comparisons of the 7-day and 14-day 
primaquine regimens with the placebo. Randomisation was done using STATA version 
14.1 (StataCorp, College Station, TX, USA), which generated blocks of 20 for each 
dosing band. The independent statistician responsible for generating the randomisation 
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list and for selecting code letters for PQ/placebo was otherwise uninvolved in the 
conduct of the trial and did not visit any of the study sites. Identical PQ/placebo tablets 
were manufactured by Centurion Laboratories (Vadodara, India) and blister packed 
(Bilcare Research, Pune, India).  Randomisation to the body weight-based regimen 
allocation provided in sequentially numbered boxes was performed at enrolment. 
Participants and all the study team were masked to treatment assignments.  
3.2.4 Procedures 
All patients enrolled were admitted to the hospital and treated with chloroquine (total 
dose of 25 mg base/kg) for 3 days as the first line treament for acute P. vivax infection. 
The study drug (primaquine or placebo) was started on day 0. Patients in the PQ7 were 
treated with either 7 days of daily primaquine 1.0 mg/kg per day  followed by 7 days of 
daily placebo (PQ7), while patients in PQ14 were treated with 14 days of daily 
primaquine 0.5 mg/kg per day (7 mg/kg total dose) (PQ14), and those in the placebo 
group received 14 days of daily placebo (90% starch, calcium phosphate). Primaquine 
was administered as 15 mg tablets. Treatment was fully supervised and dosed according 
to body weight. In children weighing less than 23 kg, tablets were dissolved in 5 ml of 
syrup and administered as a suspension.  
At enrolment, a medical history was taken, a physical examination was performed and 
antimalarial tretament with chloroquine was initiated. After completion of treatment, 
patients were asked to return weekly until day 42 and then monthly for one year. At 
each visit, a medical history was taken, a symptom questionnaire was done, and any 
adverse events (AEs) or serious adverse events (SAEs) were recorded. Patients were 
encouraged to report to the study staff  if they became ill. Those who missed their 
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scheduled follow up visits were contacted by study staff and encouraged to return to 
the study centre for review. Blood films were examined immediately for all 
symptomatic patients, but otherwise stored for later examination. Recurrent 
parasitaemia with any Plasmodium species within 28 days was considered a treatment 
failure and treated with artemisinin combination therapy (ACT). After 28 days, patients 
with recurrent symptomatic vivax parasitaemia were prescribed the same treatment 
allocated at enrolment. Patients presenting with their third or subsequent symptomatic 
P. vivax recurrence were treated with open-label supervised primaquine (0.5 mg/kg for 
14 days).  
At the initial screening, venous blood was collected and tested for G6PDd, using the 
qualitative FST (R&D Diagnostics; Athens, Greece). Standard thick (using 6l blood 
on a 12 mm diameter template) and thin malaria films were prepared at each visit for 
Giemsa staining (3%, 40-50 min) according to procedures based on the Research 
Malaria Microscopy Standard [39]. Blood films were declared negative if no parasites 
were detected after examining 200 high power fields (1000x magnification) on the thick 
film. Parasite counts were obtained from thick or thin films at each of the study sites by 
counting the number of asexual parasites on a minimum of 40 high power fileds or per 
2000 erythrocytes. Parasite densities were estimated based on calculated volumes of 
blood examined per 40 high power fields on the thick film or by assuming 5 x 106 
erythrocytes per mm3 for thin film counts. Microscopists underwent onsite training in 
study laboratory procedures and continuous quality control was implemented at all 
sites. Haemoglobin concentration was checked at each visit (HemoCue; Angelholm, 
Sweden).  
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3.2.5 Outcomes 
The primary endpoint was defined as the incidence rate of symptomatic P. vivax 
parasitaemia (mono-infection or mixed) over 12 months. The primary analysis was the 
difference in incidence rate between patients treated with 7-day and 14-day primaquine. 
The secondary efficacy endpoint included the incidence rate and incidence risk (time-
to-event analysis) of any (symptomatic and asymptomatic) P. vivax parasitaemia, 
comparing the treatment arms to each other and with the placebo group. Other efficacy 
endpoints were the incidence risks of P. vivax at 28 and 42 days, and the proportions of 
patients with P. vivax parasitaemia and/or fever on days 1, 2, and 3. The number of 
recurrences avoided per 1000 patients and the number needed to treat (NNT) to avoid 
one recurrence were derived from the rate difference.  
Safety endpoints were defined as the incidence risk of severe anemia (Hb < 7 g/dl) or 
transfusion, an acute drop in Hb > 5 g/dl within 7 days, Hb concentration on day 3 and 
7, the median time to Hb nadir, grade 3 or 4 AEs within 42 days and SAEs. The 
relationship between treatment and AEs or SAEs was determined by the site 
investigator.  
3.2.6 Sample size and statistical analysis  
The primary objective of this trial is to demonstrate the non-inferiority of PQ7 regimen 
to the standard PQ14 regimen with respect to incidence rate of vivax symptomatic 
parasitaemia over 12 months. The sample size calculation is based on the assumption 
that incidence rate of 0.2 recurrences per person-year (PPY) in both primaquine arms, 
a non-inferiority margin of 0.07 recurrences per person-year and a one-sided 
significance level of 2.5%. From this assumption, total sample size of 1200 eligible 
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patients, randomly assigned to receive a primaquine regimen, followed for one year 
provided a power of 80% to show the non-inferiority that the two-sided 95% confidence 
interval for the difference in incidence rate of malaria between the two arms excluded 
an excess rate of 0.07 recurrences per person-year or more in favour of the PQ14 
regimen. In the control arm (placebo), a further 300 patients were also followed for one 
year. With 1500 patients in which 600 patients in each primaquine arms (PQ7 and 
PQ14) and 300 patients in the control arm, the study has 95% power to detect a 
difference with the assumption that an incidence rate of 0.2 recurrences PPY in each of 
the primaquine arms and 0.6 recurrences PPY in the control arm. The losses to follow-
up and major protocol violations was expected to be no more than 20%, a planned total 
of 1875 G6PD normal patients (750 per primaquine arms and 375 in the control arm) 
will be randomized in this trial. For each of the study sites including Vietnam site, the 
target sample size of 375 patients was required as follow 150 patients for each 
primaquine arms and 75 patients in the control arm. The total of 375 patients per study 
sites also has the power of 80% to detect the non-inferiority between PQ7 and PQ14 
regimens; and the power of 95% to detect the superiority between the primaquine arms 
and the control arm.  
Statistical analyses were performed with the use of R software, version 3.6.1. The 
primary outcome was analysed on an intention-to-treat population which included all 
randomized patients who fulfilled the enrolment criteria. The distribution of the 
demographic and clinical variables collected at baseline were presented for each arm 
using mean and standard deviation (SD) for normally distributed continuous variables, 
median (25th – 75th percentile) for non-normally distributed continuous variables, and 
frequency (per cent) for categorical variables. The incidence rate of symptomatic and 
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asymptomatic recurrent P. vivax for each treatment arm and the control arm were 
calculated by the total number of recurrent P. vivax infections divided by the total 
number of person-years at risk. The incidence rate of symptomatic and asymptomatic 
recurrent P. vivax was compared between the 7-day and 14-day primaquine treatment 
arms by calculating the absolute incidence rate difference and two-sided 95% 
confidence interval. The 7-day treatment was considered non-inferior to the 14-day 
treatment if the upper limit of the confidence interval is lower than 0.07 recurrences per 
person-year. The incidence risk and the absolute risk difference (two-sided 95% CIs) 
of recurrent P. vivax within 12 months follow-up were calculated using survival 
analysis Kaplan-Meier estimates as well as Cox regression analysis for the time to first 
recurrent P. vivax. Comparisons were made between the treatment arms and control 
groups and statistical comparisons of the groups assessed using the log rank test. The 
incidence risk of severe anaemia and blood transfusion within 12 months follow-up and 
the absolute risk difference between groups were calculated. For serious adverse events 
including serious haematological events and gastrointestinal tolerability, the absolute 
difference between treatment groups in the proportion of patients (two-sided 95% CI) 
with each outcome were calculated.  
3.3 Results  
Overall, a total of 11585 patients were screened for inclusion into the study between 
July 2014 and Nov 2017. Of whom, 2336 patients were randomized into either PQ7 (n 
= 935), PQ14 (n = 937), or placebo (n = 464). By country, about half (42.8% [n = 1000]) 
of the 2336 subjects were from Indonesia; the rest were either from Ethiopia (24.8% [n 
= 580]), Afghanistan (18.5% [n = 431], or Vietnam (13.9% [n = 325]). At Vietnam site, 
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the study screened 771 patients for the eligibility of the study, of whom 426 did not 
meet the enrolment criteria and 20 were G6PD deficient. Subsequently, 325 subjects 
were enrolled into the study and assigned to receive either PQ7 (n=128), PQ14 (n=133), 
or placebo (n=64) (Figure 3.1).   
 
Figure 3.1: Trial profile in Vietnam  
G6PD=glucose-6-phosphate dehydrogenase; ITT=intention-to-treat; FU=follow-up; PP=per protocol 
Discontinuation includes: Consent withdrawn, Ineligible selection, Non-compliance with study protocol, 
Study terminated.  
In Vietnam, the subjects were enrolled from two locations: Binh Phuoc province (n = 
219) and Gia Lai province (n = 106). A majority of paticipants (85.8%) were male with 
the median age of 24 years old. While in other study sites, more than half of the 
participants (62.8%) were male, and the median age of enrolled subjects was younger 
(16 years old). At enrollment, the average temperature of subjects was 38.80C (SD 
1.01), and the geometric mean asexual P. vivax parasite density was 7,407 (95%CI: 
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6,407 – 8,562) parasites/l. The proportion of gametocytes appearance at admission 
was about 75% of the subjects. The mean level of haemoglobin concentration of 
participants was 13.5 g/dL (SD 1.53). About half of the participants (57.8%) did not 
have fever at enrollment. Baseline characteristics were not significantly different 
among three groups (Table 3.1).  Among subjects enrolled into the study, one patient 
(1.6%) in the placebo group failed to complete the initial 14-day treatment, while the 
numbers in PQ7 and PQ14 groups were 7/128 (5.5%) and 4/133 (3.0%), respectively. 
Related to the vomiting of study drugs within one hour of dosing, 1.6% (2/128), 1.5% 
(2/133) of participants in PQ7 and PQ14 were recorded, respectively while there was 
no reported case in the placebo group.     
Table 3.1: Baseline characteristics 
Characteristics 
Placebo 
(n = 64) 
PQ7 
(n = 128) 
PQ14 
(n = 133) 
Total 
(n = 325) 
Study sites 
- Dak O & Bu Gia 
Map 
- Krong Pa 
 
43 
21 
 
87 
41 
 
89 
44 
 
219 
106 
Age (years) 23 (16-31) 24 (17-30) 24 (17-32) 24 (17-31) 
Male 59 (90.6%) 104 (81.2%) 117 (88.0%) 280 (85.8%) 
Weight (kg) 
54.0 
(47.2-60.0) 
54.0 
(47.0-60.0) 
53 
(48.0-60.0) 
54 
(47.0-60.0) 
Temperature (˚C) 38.9 (1.04) 38.7 (1.01) 38.8 (0.99) 38.8 (1.01) 
Haemoglobin (g/dL) 13.6 (1.54) 13.5 (1.58) 13.5 (1.50) 13.5 (1.53) 
Plasmodium vivax 
parasites per L* 
9534 
(7088 – 
12823) 
7345 
(5771 – 
9348) 
6612 
(5258 – 
8315) 
7407 
(6407 – 
8562) 
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Data are presented as n (%), median (IQR), or mean (SD), unless otherwise indicated.  
*Data are geometric mean (95% normal range).  
Overall, chloroquine had a high efficacy against the parasite blood stage and was similar 
among three groups. A majority of patients (92.0% [n = 299]) became afebrile within 
24 hours. And, the peripheral parasitaemia was cleared within two days of the treatment 
in 87.4 % (n = 284) of the participants (Table 3.2).  
Table 3.2: Parasite and fever clearance 
 Placebo 
(n = 64) 
PQ7 
(n = 128) 
PQ14 
(n = 133) 
Fever on Day 1 19/64 (29.7) 46/128 (35.9) 45/133 (34.1) 
Fever on Day 2 5/64 (7.8) 12/128 (9.4) 9/133 (6.8) 
Fever on Day 3 1/64 (1.6) 2/128 (1.6) 1/133 (0.8) 
Asexual P. vivax parasitaemia on Day 1 57/64 (89.1) 112/128 (87.5) 120/133 (90.2) 
Asexual P. vivax parasitaemia on Day 2 10/64 (15.6) 16/128 (12.5) 15/133 (11.3) 
Asexual P. vivax parasitaemia on Day 3 1/64 (1.6) 0/128 (0) 0/133 (0) 
Fever was defined as either an axillary temperature > 37.5°C. 
Among the participants received the treatment, no reappearance of P. vivax 
parasitaemia within 28 and 42 days after the enrollment was reported in three groups. 
The cumulative risk in both asymptomatic and symptomatic P. vivax recurrence at day 
Gametocyte presence  45 (70.3%) 96 (75%) 101 (75.9%) 242 (74.5%) 
Gametocytes per L* 
169 
(101 – 283) 
187 
(132 – 265) 
177 
(129 – 243) 
180 
(146 – 221) 
  
 
 
 
71 
 
28 and 42 was 0% in all the participants regardless the treatment group they belonged 
to. 
After one year, the incidence rate of symptomatic recurrent P. vivax malaria was 0.132 
(95% CI, 0.065 – 0.199) episodes per person-year (PPY) following PQ7, 0.143 (95% 
CI, 0.075 – 0.211) episodes PPY following PQ14 and 1.105 (95% CI, 0.825 – 1.384) 
episodes PPY in the placebo group (Table 3.3). Between the PQ7 and PQ14 groups, the 
incidence rate difference (IRD) was -0.0105 (95% CI, -0.0106 - -0.00848; p = 0.8277). 
This difference (IRD = -0.0105) was within the pre-defined non-inferiority margin of 
0.07. The incidence rate ratio (IRR) was estimated as 0.926 (95% CI: 0.462 - 1.854; 
p=0.8278). The number of recurrences avoided per 1,000 patients was 971 for PQ7 
(NNT=1.03, 95% CI: 0.79 – 1.46) and 962 for PQ14 (NNT=1.04, 95% CI: 0.8 – 1.46).   
The incidence rate of any recurrent vivax malaria (both symptomatic and 
asymptomatic) at 1 year was 0.194 (95% CI, 0.113 – 0.275) episodes PPY following 
PQ7 and 0.143 (95% CI, 0.075 – 0.211) episodes PPY following PQ14. These rates 
were significantly lower than in the placebo group (1.454 [95% CI, 1.134 – 1.775] 
episodes PPY) with IRR =  0.13 (95% CI, 0.08 – 0.21; p<0.001) for PQ7 versus placebo 
and IRR = 0.098 (95% CI, 0.058 – 0.166; p<0.001) for PQ14 versus placebo (Table 
3.4). 
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Table 3.3: Recurrence data per treatment group 
 Placebo 
(n = 64) 
PQ7 
(n = 128) 
PQ14 
(n = 133) 
Follow-up time (person-years) 54.32 113.34 118.93 
Symptomatic P. vivax recurrence (episode) 60 15 17 
Any P. vivax recurrence (episode) 
(symptomatic & asymptomatic) 
79 22 17 
Incidence rate of symptomatic P. vivax 
recurrence (episodes PPY; 95% CI) 
1.105 
(0.825-1.384) 
0.132 
(0.065-0.199) 
0.143 
(0.075-0.211) 
Incidence rate of any P. vivax recurrence 
(episodes PPY; 95% CI) 
1.454 
(1.134-1.775) 
0.194 
(0.113-0.275) 
0.143 
(0.075-0.211) 
Cumulative risk of symptomatic P. vivax 
recurrence after one year  (95% CI)  
58.4%  
(43.7-69.2) 
9.5%  
(4.00 – 14.6) 
12.4%  
(6.3 – 18.1) 
 
Table 3.4: Incidence rate ratio between treatment arms 
 PQ7 vs Placebo PQ14 vs Placebo PQ7 vs PQ14  
 IRR p IRR p IRR p 
Symptomatic P. 
vivax 
parasitemia 
0.12 
(0.068-0.211) 
< 0.01 
0.129 
(0.076-0.222) 
< 0.01 
0.926 
(0.462-1.854) 
0.83 
Any P. vivax 
parasitemia 
0.13 
(0.08-0.21) 
< 0.01 
0.098 
(0.058-0.166) 
< 0.01 
1.358 
(0.721-2.557) 
0.34 
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In the time to first event analysis, the cumulative risk of symptomatic P. vivax at one 
year was 9.5% (95% CI, 4.00 – 14.6) after PQ7 and 12.4% (95% CI, 6.3 – 18.1) after 
PQ14. These cumulative risks in both primaquine treatment groups were similar (p = 
0.506). Both of these risks are significantly lower than the risk of 58.4% (95% CI, 43.7 
– 69.2) in the placebo group (HR = 0.10 [95% CI, 0.05 – 0.20]; p<0.001 and HR = 
0.356 [95% CI, 0.263 – 0.483]; p<0.001), respectively (Figure 3.2).  
Figure 3.2: Kaplan Meier curves for symptomatic P. vivax recurrence. 
From Vietnam site, during the trial, a total of 4 serious adverse events were reported. 
In PQ7 group, there was one haemolytic serious adverse event. This patient was a 
G6PDd male who had been enrollled erroneously into the PQ7 group. The event 
occured 5 days after initiation of the treatment. His Hb level dropped from 15.3 to 6.4 
g/dL accompanied with dark urine colour. He required hospilization and a blood 
transfusion. His clinical condition and Hb concentration improved later on. The other 
serious adverse event was associated with gastrointestinal disturbance. This was a 
patient with diarrhea symptom appeared on day 7 after the treatment. The patient was 
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required to admit into the hospital for fluid supplement therapy and close monitoring. 
The study drugs were temporarily discontinued. Symptoms resolved within 5 days and 
he continued to complete the entire regimen afterwards.  In PQ14 group, one subject 
with the diagnosis of undifferentiated carcinoma in nasophaynx during the follow up 
time (Month 5) was recorded. While in placebo group, one subject with severe P. 
falciparum malaria infection appeared at month 6 of follow up time, needed 
hospitalised and received intravenous artesunate treament (Table 3.5).  
Table 3.5: Severe adverse events and adverse events (grade 3 – 4) 
 Placebo 
(n=64) 
PQ7 
(n=128) 
PQ14 
(n=133) 
≤ Day 42 
SAE (Primaquine-related)  0 2 (1.6%) 0 
SAE (Primaquine unrelated) 0 0 0 
AE (Grade 3 and 4)  0 1 (0.8%) 0 
≤ 1 year 
SAE (Primaquine-related)  0 2 (1.6%) 0 
SAE (Primaquine unrelated) 1 (1.6%) 0 1 (0.8%) 
Adverse events within 42 days with a severity grade of 3 or 4 were reported in one 
subject that received the 7-day primaquine course. This event was related to 
gastrointestinal symptoms. This patient was suffered from vomiting, watery diarrhea 
after 4 days of treatment initiation and recovered within one day. All of them belonged 
to the PQ 7 arm. These events involved gastrointestinal discomfort,  
During the period of treatment, 87 (33.3%) of 261 patients in the primaquine group 
reported any gastrointestinal discomfort, which was higher compared with the placebo 
group (4/64 [6.3%], p < 0.001). This number in the 7-day primaquine group (72/128 
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[56.3%]) was significantly greater than one in the 14-day group (15/133 [11.3%], p < 
0.05) or the placebo group (4/64 [6.3%], p < 0.05) (Table 3.5). Most of the events were 
mild in severity, appeared within 5 days after the treatment and improved after 3 – 5 
days of temporary study drug discontinuation. 
Table 3.6: Symptoms elicited from daily questionnaires during treatment time  
(Day 1– 14) 
 Placebo 
(n=64) 
PQ7 
(n=128) 
PQ14 
(n=133) 
p value 
Placebo vs PQ PQ7vsPQ14 
≤ 1 hour 
Vomiting 
study drug 
0 2 (1.6%) 2 (1.5%) NA > 0.05 
Day 1-3 [1] 
Fever 
20 
(31.3%) 
48 
(37.5%) 
44 
(33.1%) 
> 0.05 > 0.05 
Headache 
14 
(21.9%) 
35 
(27.3%) 
24 
(18.0%) 
> 0.05 > 0.05 
Vomit 1 (1.6%) 3 (2.3%) 1 (0.8%) > 0.05 > 0.05 
Abdominal 
pain 
1 (1.6%) 4 (3.1%) 2 (1.5%) > 0.05 > 0.05 
Diarrhoea 1 (1.6%) 2 (1.6%) 0  > 0.05 NA 
Poor 
appetite 
1 (1.6%) 1 (0.8%) 2 (1.5%) > 0.05 > 0.05 
Itching 0  0  2 (1.5%) NA NA 
Skin rash 0 1 (0.8%) 2 (1.5%) NA > 0.05 
Myalgia / 
Arthralgia 
0 2 (1.6%) 0 NA NA 
Dizziness  0 1 (0.8%) 0 NA NA 
Shortness 
of breath  
0 0 0 NA NA 
Passing 
dark urine 
0 0 0 NA NA 
Any GI 
symptoms 
[2] 
4 (6.3%) 10 (7.8%) 5 (3.8%) > 0.05 < 0.05 
Day 4-14 [1] 
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 Placebo 
(n=64) 
PQ7 
(n=128) 
PQ14 
(n=133) 
p value 
Placebo vs PQ PQ7vsPQ14 
Fever 2 (3.1%) 9 (7.0%) 7 (5.3%) > 0.05 > 0.05 
Headache 0 1 (0.8%) 1 (0.8%) NA > 0.05 
Vomit 0 
15 
(11.7%) 
1 (0.8%) NA < 0.05 
Abdominal 
pain 
0 
26 
(20.3%) 
7 (5.3%) NA < 0.05 
Diarrhoea 0  
13 
(10.2%) 
2 (1.5%) NA < 0.05 
Poor 
appetite 
0 8 (6.3%) 0 NA NA 
Itching 0  1 (0.8%) 1 (0.8%) NA > 0.05 
Skin rash 0 2 (1.6%) 1 (0.8%) NA > 0.05 
Myalgia / 
Arthralgia 
0 0 0 NA NA 
Dizziness  0 0 0 NA NA 
Shortness 
of breath  
0 0 0 NA NA 
Passing 
dark urine 
0 1 (0.8%) 0 NA NA 
Any GI 
symptoms 
[2] 
0  
62 
(48.4%) 
10 (7.5%) < 0.01 < 0.05 
[1]: Number of patients with daily symptom questionnaires during treatment course. 
[2]: Composite of any of the following: nausea, vomiting, anorexia, diarrhoea, or 
abdominal pain.  
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The median time to haemoglobin nadir in the placebo group as well as in both 
primaquine groups was similar with on day 3 after the starting of treatment. The mean 
absolute decreases in haemoglobin at day 3 were 0.41 g/dL (SD 0.99) in the 7-day 
primaquine group, 0.50 g/dL (1.04) in the 14-day group, and 0.54 g/dL (0.96) in the 
placebo group. The corresponding mean percentage change in haemoglobin between 
day 0 and day 3 was -2.84% (SD 7.36) in the 7-day group, -3.40% (7.73) in the 14-day 
group, and -3.79% (7.04) in the placebo group. At day 7, the mean absolute increases 
in haemoglobin in the 7-day and placebo group was 0.20 g/dL (SD 1.24) and 0.04 g/dL 
(1.27), respectively; while the mean absolute decrease haemoglobin in the 14-day group 
was 0.01 g/dL (1.07) (Table 3.6; Figure 3.3). The incidence risk of severe anaemia was 
0.8% in 7-day regimen; while this was none in the 14-day and placebo group. This 
patient was erroneously randomized into the PQ 7 group despite deficient G6PD status. 
Boxes represent median; 25th and 75th percentile 
Figure 3.3: Distribution of haemoglobin during follow up time by treatment group. 
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Table 3.6: Haemoglobin profile by treatment group 
 Placebo 
(n=64) 
PQ 7  
(n=128) 
PQ 14  
(n=133) 
Incidence risk of severe anaemia (<7 
g/dL) or transfusion within 365 days, N 
(%) 
0 1 (0.8) 0 
Hb drop > 5 g/dL within 7 days of initial 
treatment N (%) 
0 0 0 
Hb nadir within 28 days of treatment 
initiation, g/dL, mean [SD] 
12.72 [1.4] 12.54 [1.4] 12.55 [1.3] 
Time to Hb nadir, days, median (range)  3 (3-7) 3 (3-13) 3 (3-13) 
Day 0  
Number of patients  64 128 133 
Hb on day 0, g/dL, mean [SD] 13.62 [1.5] 13.46 [1.6] 13.54 [1.5] 
Day 3 
Number of patients  63 124 129 
Hb on day 3, g/dL, mean [SD] 13.08 [1.5] 13.03 [1.5] 13.07 [1.4] 
Change in Hb between Day 0 and Day 
3, g/dL, mean [SD] 
-0.54 [0.96] -0.41 [0.99] -0.50 [1.04] 
Absolute drop between Day 0 and Day 
3 > 5 g/dL, N (%) 
0 0 0 
Fractional change in Hb between Day 0 
and Day 3, %, mean [SD]  
-3.79 [7.04] -2.84 [7.36] -3.40 [7.73] 
Fractional drop between Day 0 and Day 
3 > 25%, N (%)  
0 0 2 (1.5) 
Day 7  
Nummber of patients 64 117 124 
Hb on day 7, g/dL, mean [SD] 13.65 [1.6] 13.67 [1.6] 13.52 [1.4] 
Change in Hb between Day 0 and Day 
7, g/dL, mean [SD] 
0.04 [1.27] 0.20 [1.24] -0.01 [1.07] 
Absolute drop between Day 0 and Day 
7 > 5 g/dL, N (%) 
0  0 0 
Fractional change in Hb between Day 0 
and Day 7, %, mean [SD]  
0.69 [9.81] 1.90 [9.56] 0.28 [8.12] 
Fractional drop between Day 0 and Day 
7 > 25%, N (%)  
0 0 0 
Day 13 
Number of patients  62 119 129 
  
 
 
 
79 
 
 Placebo 
(n=64) 
PQ 7  
(n=128) 
PQ 14  
(n=133) 
Hb on day 13, g/dL, mean [SD] 13.69 [1.4] 13.41 [1.4] 13.59 [1.3] 
Change in Hb between Day 0 and Day 
13, g/dL, mean [SD] 
0.07 [1.19] -0.07 [1.20] 0.03 [1.04] 
Absolute drop between Day 0 and Day 
13 > 5 g/dL, N (%) 
0 0 0 
Fractional change in Hb between Day 0 
and Day 13, %, mean [SD]  
1.09 [9.0]  0.0 [9.37] 0.70 [8.10] 
Fractional drop between Day 0 and Day 
13 > 25%, N (%)  
0 0 0 
Day 28  
Number of patients 51 112 112 
Hb on day 28, g/dL, mean [SD] 14.17 [1.4] 13.93 [1.3] 13.87 [1.4] 
Day 42 
Number of patients 50 110 100 
Hb on day 42, g/dL, mean [SD] 14.24 [1.61] 14.12 [1.45] 14.28 [1.34] 
3.4 Discussion 
The results from Vietnam together with other sites of this placebo-controlled trial 
confirm the high antirelapse efficacy of primaquine at a total dose of 7 mg/kg in a short 
course regimen of 7 days. Furthermore, the results from Vietnam shows the high 
incidence of recurrence vivax parasitaemia if primaquine treatment is not prescribed. 
This supervised course of 7-day high dose primaquine prevented 971 recurrences per 
1,000 patients , and the 14-day regimen prevented 962 recurrences per 1,000 patients. 
The 7-day regimen was proved to be non-inferior in preventing vivax recurrences to the 
standard 14-day regimen. Though the haemolytic risks of two primaquine regimens 
were not different, the frequencies of gastrointestinal intolerance were higher in 7-day 
short course compared with 14-day course despite both being administered with food 
per protocol.  
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In combination with schizonticidal drugs (chloroquine or the artemisinin derivative), 
primaquine has been recommended as a hypnozoiticical agent for more than 60 years 
in order to achieve the radical cure of P. vivax malaria [52]. The major safety concern 
in primaquine usage is the haemolytic toxicity in G6PD deficient patients [158]. The 
WHO recommends the screening for G6PD status before the use of primaquine. 
However, in most malaria endemic countries, there is currently no available and reliable 
G6PD testing, primaquine is rarely used due to the concerns over safety. In Vietnam, 
the primaquine radical treatment is recommended from national guideline in preventing 
vivax relapse. However, this administration is usually withheld by most of the 
healthcare workers because of the lack of G6PD rapid diagnostic test as well as the fear 
of primaquine-induced haemolysis. The antirelapse efficacy of primaquine is related to 
the total dosage, while the hemolytic toxicity as well as gastrointestinal disturbance 
depends on the daily dose administration [159]. While the widely acceptable duration 
of primaquine regimen is 14-day, the compliance to such a long course of treatment in 
most malaria endemic regions may be relatively low [153, 160]. In this study, we found 
not only the non-inferiority anti-relapse efficacy but also the acceptable safety profile 
between the 7-day primaquine regimen and the 14-day regimen in G6PD normal 
patients.  
The findings from this trial have firstly demonstrated the true relapse pattern of vivax 
malaria in different endemic regions and the high antirelapse efficacy of primaquine at 
the total dose of 7 mg/kg compared with no primaquine. If no hypnozoitocidal drugs 
were prescribed, the cumulative risk of recurrence at one year of follow-up could reach 
above 50% in Vietnam and other sites. However, at the two Indonesia sites, the 
incidence risks of symptomatic vivax recurrence were 39.33% (95% CI 30.31–49.92) 
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and 28.59% (19.39–40.90) after treatment with dihydroartemisinin-piperaquine alone 
[157]. And when primaquine therapy was applied, this incidence risk of recurrent vivax 
parasitaemia decreased dramatically to around 15%. This present study showed that the 
supervised course of 7-day high dose primaquine prevented 971 recurrences per 1,000 
patients, and the 14-day regimen prevented 962 recurrences per 1,000 patients. 
Primaquine is generally recommended as a 14-day course for radical cure of P. vivax 
malaria, the optimum dose and duration is still debated. The long duration of this 
regimen could reduce the adherence of patients, hence influence the efficacy of the 
therapy. Previous studies have shown that adherence to a full course of 14 days is often 
poor [68, 161, 162]. In one study from Thailand, the migrant populations along the 
borders, poor compliance to primaquine has been well documented [68, 161, 162]. A 
study in Afghanistan showed that 11/139 (8%) non-adherent subjects contributed 36 
recurrences compared to 6/170 (4%) adherent individuals who contributed 19 
recurrences [160]. Under supervision, the short 7-day primaquine regimen was shown 
to be non-inferior compared with the standard 14-day regimen. This shorter regimen 
could help to enhance the compliance of the patients, hence improve the effectiveness 
of the therapy in field settings. Owing to the high frequent relapse rate in vivax malaria, 
there was a high demand to implement this short course of primaquine together with 
site-specific approaches in order to reach the elimination goal.  
Individual dosing of primaquine is limited by abdominal discomfort described as 
nausea, vomiting, abdominal pain and diarrhea.  This is often severe at doses over 1 mg 
base/kg. In general primaquine is well tolerated at individual doses ≤0.5 mg base/kg if 
given together with food [76]. In this trial, patients in the 7-day primaquine group 
received twice the daily dose in the standard 14-day high dose regimen (0.5 mg/kg/day) 
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and 4 times higher than that in the 14-day low dose regimen (0.25 mg/kg/day) 
recommended by national control malaria program [45]. The results from multisite trial 
illustrated the low rate of vomiting study drug within one hour of administration as well 
as the comparable percentage of patients reported gastrointestinal discomfort between 
1 mg/kg per day and 0.5 mg/kg per day groups. Regards to Vietnam site, there was also 
similarity in the occurrence of vomiting, however patients with higher daily dose (1 
mg/kg per day) were more likely to report abdominal disturbance. These symptoms 
generally occurred early, were mild in severity and resolved within 72 hours. The 
gastrointestinal tolerability can be improved by taking primaquine with food [75]. 
Although shortening the duration of treatment might potentially improve adherence, a 
higher daily dose increases the risk of haemolysis and gastrointestinal disturbance. 
While these adverse events can be reduced by the reliable G6PD rapid diagnostic tests 
and food co-administration, the disadvantages of short course high dose primaquine 
could affect the tolerability and hence the adherence when implementing in malaria 
fields.  
All of the patients enrolled into the study were screened for G6PD deficiency using the 
FST, a qualitative assay that identifies individuals with less than 30% enzyme activity 
[163]. The FST has a sensitivity and specificity above 95% for the diagnosis of G6PD 
deficiency in adults with less than 30% enzymatic activity [110]. While this approach 
can exclude G6PDd hemizygous males and homozygous females, heterozygous 
females with intermediate G6PD activity (30 – 70%) tested as G6PD “normal” and 
were enrolled. With the usage of primaquine, the haemolytic risk in both 7-day and 14-
day course was similar to the placebo. The occurence of one haemolysis anaemia 
serious adverse event in the 7-day because of errornous G6PD diagnosis. The 
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distribution of hemoglobin changes during the treatment course was identical among 
three groups. In combination with the reliable G6PD diagnostic tests and the early 
detection of any signs of haemolysis, the severity of haemolytic anaemia could be 
prevented when 7-day short course of primaquine is implemented. Tafenoquine, a 
slowly eliminated 8-aminoquinoline, recently licensed in the USA and Australia, 
achieves radical cure with only a single dose when combined with standard chloroquine 
therapy [164]. Although Tafenoquine can enhance the effectiveness of the radical cure, 
the prolonged exposure results in lengthy haemolysis, even in G6PDd heterozygous 
females. For this concern, the use of Tafenoquine is only restricted in subjects with > 
70% G6PD enzyme activity. The determination of G6PD enzyme activity at 70% 
threshold demands a highly complex quantitative test. This will add cost and 
infrastructure to the overall malaria endemic communities. Furthermore, tafenoquine is 
now only licensed to be prescribed in subjects older than 16 years, while primaquine is 
safely indicated in patients with G6PD activity more than 30% and age more than 6 
months. Furthermore, thank to the rapid elimination and daily administration, the risk 
of haemolysis of primaquine can be identified and managed timely whenever the 
hemolytic signs appear.  
The findings of this study should of course be considered in context of strengths and 
weaknesses. The study was based on a large, well characterized cohort who was 
recruited from four vivax malaria endemic countries. Thus, the estimates presented here 
are likely to reflect the situation in other vivax endemic regions. To our knowledge, this 
is the first study that helps to identify the true relapse pattern and the efficacy of 
primaquine with long follow-up time. The main limitation is the inadequate of sample 
size. The study did not reach the target sample size although a large number of patients 
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had been screened (325 participants per 771 screened) mainly due to study early 
termination. However, the non-inferiority of efficacy between PQ7 and PQ14 regimen, 
the primary objective, was demonstrated to be within the margin of 0.07. Multi-site 
analysis as well as single site sub-analysis also showed the comparable of antirelapse 
efficacy between the two primaquine therapies [157]. In PQ14 group, all of the 
recurrence episodes (n = 17) were symptomatic, which was different from PQ7 group. 
Until now, the clear underlying cause could not identified.  
In summary, in vivax malaria endemic regions where the incidence risk of recurrent 
parasitaemia is substantial high (~50% at one year follow-up), primaquine therapy with 
dose of 7 mg/kg showed the superiority of antirelapse efficacy compared with single 
schizontocidal treatment. The efficacy of a shorter 7-day regimen of primaquine was 
non-inferior to the standard 14-day regimen in normal G6PD patients and had an 
acceptable safety and tolerability profile. The shorter the course of treatment, the more 
facile the adherence of patients; therefore improve the effectiveness of radical cure in 
vivax-endemic countries. The available of qualitative G6PD rapid diagnostic test at the 
30% threshold could ameliorate the wide-spread coverage this short primaquine 
regimen. 
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Chapter 4 
Safety and efficacy of Tafenoquine as a radical cure for adult subjects 
with Plasmodium vivax when co-administered with chloroquine 
4.1 Introduction 
Plasmodium vivax and Plasmodium falciparum are the primary causes of malaria in 
humans. Both parasite species expose approximately 2.5 billion people to the risk of 
infection [165]. Although P. falciparum causes many deaths, especially in sub-Saharan 
Africa, P. vivax is predominant in South East Asia, South America, the world’s most 
densely populated regions [5]. Vivax malaria infection coupled with its now proven 
association with severe and fatal outcomes impose its importance in reducing the 
incidence [165]. The most apparent characteristic of P. vivax is the ability to cause 
relapses weeks to months following a primary infection by activation of dormant liver-
stage parasites, known as hypnozoites [166]. The hypnozoites cause multiple clinical 
attacks from a single bite of a P. vivax-infected mosquito. Relapses caused 
approximately 50% of blood-stage infections and more than 60% of clinical episodes 
in the first 3 months [73]. Relapse may be the predominant origin of most P. vivax 
clinical attacks throughout the endemic world [73]. The elimination of P. vivax 
infection requires the combination treatment of blood schizonticide to cure the primary 
blood infection and hypnozoiticide to kill the hypnozoite in the liver [167]. Primaquine, 
an 8-aminoquinoline, was first licensed for use in the 1950s by the Food and Drug 
Administration (FDA), United States, for treatment of vivax hypnozoites [168]. 
Without administration of primaquine in adequate doses, complete cure of patients with 
P. vivax is difficult, and patients often have relapses of clinical cases. Primaquine 
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treatment has to be continued for 14 days, which often leads to poor compliance. A 
search for a replacement drug for primaquine in its curative role has been ongoing for 
the last few decades. Tafenoquine, like primaquine, has the effect on clearing the 
dormant P. vivax parasites in infected patients to prevent a relapse [169]. Tafenoquine 
is shown promising results for both prevention and radical cure in individual trials [92, 
93, 170-173]. With a longer half-life, tafenoquine has the advantage with only single 
dose of 300 mg to increase the adherence in preventing the relapses compared with 14-
day course of primaquine. The efficacy of tafenoquine has been shown to reduce the 
risk of recurrent malaria at 6 months approximately 70% compared with placebo in 
patients with vivax infection in two comparative trials [88, 164]. DETECTIVE study 
identified two tafenoquine doses (300 mg and 600 mg) that, when co-administered with 
chloroquine, had significantly improved relapse-free efficacy at 6 months compared 
with chloroquine alone [88]. 
Like other 8-aminoquinoline antimalarial drugs, tafenoquine can cause hemolytic 
anemia in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. This 
Mendelian X-linked gene is one of the most highly polymorphic of the human genome 
with at least 400 mutations described [97]. G6PD deficiency is widespread across 
malaria endemic regions [96]. An overall allele frequency of deficiency of 8.0%, varied 
from 1 to 30%, was predicted across all malaria endemic countries [95]. The hemolytic 
risk with tafenoquine relative to that with primaquine has been characterized among 
healthy volunteers with normal G6PD enzyme activity and volunteers who were 
heterozygous for G6PD deficiency [174]. Our knowledge of the hemolytic risk of 
tafenoquine when administering in vivax patients is not fully understood. The aim of 
this research was thus to assess the hemolytic risk of tafenoquine, further to evaluate 
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the efficacy of tafenoquine in preventing relapse of P. vivax malaria in comparison with 
primaquine.  
4.2 Methods  
4.2.1 Trial design 
This was a phase 3, prospective, double-blind, double-dummy, randomized, controlled 
trial that was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam 
and Thailand between April 30, 2015, and November 4, 2016. The result from this 
multi-site trial has been published in The New England Journal of Medicine [89]. In 
this multi-site trial, my role was site clinical investigator. My major activities were to 
enroll the eligible subjects, manage and assess the subjects as per protocol. It was 
conducted in accordance with the International Conference on harmonization Good 
Clinical Practice guidelines, the tenets of the Declaration of Helsinki (2013), and 
relevant regulatory requirements. The ethics committee or institutional review board at 
each participating site provided ethical approval. All participants or their parents or 
guardians provided written informed consent. Assent was obtained from participants 
who were younger than 18 years of age.  
4.2.2 Participants 
Eligible patients were at least 16 years of age and had microscopically confirmed P. 
vivax (> 100 and < 100,000 parasites per microliter) and a corrected QT interval 
according to Fridericia’s formulation (QTcF) of less than 450 msec. Eligible female 
participants were not lactating, had a negative pregnancy test, and agreed to comply 
with approved contraception. The participants must have the normal G6PD activity. 
The G6PD activity was determined on the basis of a quantitative spectrophotometric 
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phenotype assay (Trinity Biotech). Before starting the trial, each study site established 
a median value for normal G6PD activity among 36 healthy male volunteers who 
otherwise were not involved in the trial. Female patients were required to have a G6PD 
enzyme level that was ≥ 40% of the site-specific normal value and male patients were 
required to have G6PD enzyme level that was ≥ 70% of the site-specific normal value. 
Patients were required to have a haemoglobin level of at least 7 g per deciliter, while 
the female patients with moderate G6PD enzyme activity were required to have a 
haemoglobin level of at least 8g per deciliter. Exclusion criteria were mixed 
plasmodium species or severe malaria, severe vomiting, an alanine aminotransferase 
level more than 2 times the upper limit of the normal range, clinically significant 
concurrent illness, use of an antimalarial drug within the previous 30 days or use of an 
investigational drug within the previous 30 days or within five half-lives (whichever 
was longer), use of concomitant drugs that could affect trial results, previous participant 
in or treatment within the trial, and a history of allergies or contraindications to 
tafenoquine, primaquine, or chloroquine.  
4.2.3 Randomization and treatments 
The study medication were chloroquine phosphate (300-mg tablets [West Ward 
Pharmaceuticals], tafenoquine (150-mg film-coated tablets [GlaxoSmithKline]), and 
primaquine phosphate (15-mg over encapsulated tablets [Sanofi]) (dosages are given 
for the free-base form). All treatments were administered orally with food. All patients 
received 600 mg of open-label chloroquine on days 1 and 2 and 300 mg on day 3. 
Subjects were assigned to study treatment in accordance with the randomization 
schedule generated prior to the start of the study. Each subject scheduled to receive 
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medication received a treatment allocation number when randomized. The 
randomization number indicated which therapy the subject will receive, the treatment 
allocation ratio was 2:1 (TQ/CQ: PQ/CQ). Once a randomization number was allocated 
to a subject, it could not be re-assigned to any other subject. Patients were randomly 
assigned, in a 2:1 ratio, to receive a single 300-mg dose of tafenoquine while 
hospitalized on day 1 or 2 or 15 mg of primaquine once daily for 14 days starting on 
day 1 or 2. To ensure that the patients and investigators were unaware of the trial-group 
assignments, primaquine-matched placebo was administered to patients in the 
tafenoquine group and tafenoquine-match placebo was administered to patients in the 
primaquine group on the scheduled treatment days. 
Table 4.1: Investigational drug schedule 
Treatment arm Day 1 Day 2 Day 3 Days 4 – 15 
Tafenoquine 2 x CQ 300mg 2 x CQ 300mg + 
2 x TQ 150mg + 
1 x PQ placebo 
1 x CQ 300mg 
+  
1 x PQ placebo 
1 x PQ placebo 
Primaquine 2 x CQ 300mg 2 x CQ 300mg + 
2 x TQ placebo + 
1 x PQ 15mg 
1 x CQ 300mg 
+ 
1 x PQ 15mg 
1 x PQ 15mg 
 
 The study medication administration was directly observed during the hospitalization 
time and the period of outpatient visits by the study staffs or healthcare workers. If the 
subject vomited within 1 hour following dosing, a repeat dose was given. If a subject 
sequentially vomited two doses of study medication, he or she was considered intolerant 
to study medication. These subjects were withdrawn from study medication. Treatment 
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was discontinued when a patient had a protocol-defined decrease in the haemoglobin 
level (> 3.0 g per deciliter or ≥ 30% from baseline or to have level of < 6.0 g per 
deciliter), clinically significant changes in the liver chemical profile, a prolongation of 
the QT interval (corrected with the use of Fridericia’s formulation) to more than 500 
msec, or a grade 4 adverse event. Only in the case of an emergency or in the event of a 
serious medical condition, the investigators may unblind a subject’s treatment 
assignment if the individual study treatment is required for the appropriate clinical 
management.  
4.2.4 Procedures 
Trial participants were hospitalized on days 1 to 3, and the trial visits took place on 
days 5, 8, 11, and 15 during the treatment period and on days 22, 29, 60, 90, 120, 150, 
and 180 during the follow-up period. Baseline demographic data and a medical history 
were obtained at screening, and a physical examination was performed. Thick and thin 
blood smears were prepared for identification of parasites, and parasites were 
enumerated with the use of established methods [39]. Blood samples for parasitological 
assessment were obtained at screening and twice daily (every 6 to 12 hours) from day 
1 until day 3 or until parasite clearance was confirmed; smears were examined on all 
subsequent follow-up visits and after recurrence of parasitaemia or withdrawal from the 
trial. G6PD genotyping was performed at a central laboratory for participants with a 
hemoglobin decline of 3 g or more per deciliter, with the use of standard methods. 
Safety was assessed at all visits, at the time of recurrence of parasitaemia, and at 
withdrawal from the trial. Twelve-lead electrocardiography was performed at 
screening; 12 hours after the first dose of tafenoquine, primaquine, or placebo; and on 
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day 29. Analyses of hematologic and clinical chemistry values and urinalysis were 
performed at screening, on day 3, at follow-up visits until day 120, and at the time of 
recurrence of parasitaemia or withdrawal from the trial. Methaemoglobin levels were 
determined with the use of pulse oximetry at screening; on days 2, 3, 5, 8, 11, 15, 22, 
29, 60, and 120; and at the time of recurrence of parasitaemia or withdrawal from the 
trial. G6PD phenotype was determined by means of quantitative spectrophotometric 
analysis (Trinity Biotech). G6PD genotype was determined for all female patients and 
for male patients who had a protocol-defined decrease in the hemoglobin level during 
the treatment period. 
4.2.5 Trial populations and outcomes 
The safety population included all patients who underwent randomization and received 
as least one dose of a trial medication in a blinded manner. The intention-to-treat 
population was a subgroup of patients from the safety population who had 
microscopically confirmed P. vivax parasitaemia. The per-protocol population was a 
subgroup of patients from the intention-to-treat population who had no major protocol 
violations.  
In this trial, the primary safety outcome was a protocol-defined decrease in the 
hemoglobin level (> 3.0 g per deciliter or ≥ 30% from baseline or to a level of < 6.0 g 
per deciliter). Secondary safety outcomes were the occurrence and severity of adverse 
events and the occurrence of abnormal clinical laboratory test results, 
electrocardiograms, vital signs. Secondary efficacy outcomes were freedom from 
recurrence of P. vivax parasitaemia at 4 months and 6 months and other outcomes 
consistent with those in the other trial and were evaluated in the per-protocol and 
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intention-to-treat populations. Freedom from the recurrence was defined as initial 
clearance of parasitaemia (parasite numbers decreased to below the limit of detection 
in a thick blood smear and remained undetectable in a second smear collected 6 to 12 
hours later), without the patient presenting with P. vivax asexual stage parasites at any 
point in the trial, plus a negative P. vivax smear within the acceptable time window for 
the 6-month assessment.  
4.2.6 Statistical analysis 
A sample size of 300 patients – 250 male and female patients with normal G6PD 
enzyme activity and 50 female patients with moderate G6PD enzyme deficiency (> 40 
to < 70% of the site-specific normal value) – was planned in this trial. The sample size 
was determined on the basis of a regulatory requirement to obtain an appropriate overall 
safety database for tafenoquine (300 mg) in patients with P. vivax malaria who had 
normal or moderately deficient G6PD activity. Analyses were performed with the use 
of R software, version. All safety data from this trial were summarized with the use of 
descriptive statistics. For the primary safety outcome, the percentage of patients who 
had a protocol-defined decrease in the hemoglobin level in each treatment group was 
reported with 95% confidence intervals, and the absolute difference in this percentage 
between the treatment groups was reported with 95% confidence intervals.  
In this trial, the percentages of patients who were free from recurrence at 4 months 
and 6 months and the times to clearance of parasites, gametocytes, and fever were 
estimated with the use of the Kaplan-Meier method.  
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In the patient-level meta-analysis, non-inferiority of tafenoquine to primaquine with 
respect to freedom from recurrence at months was assessed in the per-protocol 
populations. The non-inferiority margins were derived from the study with the use of a 
75% preserved effect of primaquine. The non-inferiority margin was a hazard ratio for 
recurrence of 1.21, or if the assumption of proportional hazards was not met, and odds 
ratio was to be calculated. The odds ratio comparing chloroquine to primaquine in the 
phase 2b DETECTIVE trial, with adjustment for region, was 8.66 (95% confidence 
interval [CI], 2.80 to 26.85). The non-inferiority margin of 1.45 used in this trial was 
derived from taking the 75% preserved effect of the lower 95% confidence bound of 
2.80.  
4.3 Results  
From October 2015 to May 2016, globally, 251 patients were recruited in this 
GATHER trial, of whom 74.5% were from South America. Of these 251 patients, 166 
were assigned to receive chloroquine plus a single 300-mg dose of tafenoquine while 
85 others received chloroquine plus 15 mg of primaquine for 14 days. In Vietnam site, 
we screened 51 patients positive with Plasmodium vivax malaria. Of whom, 44 subjects 
fullfilled the inclusion and exclusion criteria and were finally enrolled into the study.  
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Figure 4.1: Study population from Vietnam site. 
The participants were randomized into either tafenoquine arm (n = 29) or primaquine 
arm (n = 15). During 6 months of follow-up, 43 (98%) of the subjects completed the 
study. Only one subject in tafenoquine arm could not continue the study from Day 120 
because of his own work in the hometown (Figure 4.1).   
The baseline demographic and clinical characteristics of the participants stratified by 
treatment groups are shown in Table 4.2. Thirty three (7%) of 44 subjects were male. 
The mean ( SD) age of our participants was 32  11 years. We found that 77% (n = 
34) of the patients also had gametocyte in the blood at the time of enrolment. The level 
of G6PD activity (mean  SD) was 8.4  1.9 IU/gHb, with no significant difference 
between tafenoquine and primaquine groups. The mean (SD) haemoglobin 
concentration at the baseline was 133  17.3 g/L in the primaquine group and 131  
16.3 g/L in the tafenoquine group. Demographic and baseline characteristics were 
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similar between the two arms, except for the temperature of participants at admission 
time (p = 0.03), which did not have effect on the outcome (Table 4.2). During the 
treament course of 14 days tafenoquine/placebo or primaquine, all the participants 
visited the clinics daily to take the investigational drugs. 
Table 4.2: Baseline demographic and clinical characteristics. 
Characteristics 
Primaquine  
N = 15 
Tafenoquine  
N = 29 
Total 
 N = 44 
Ethnicity (n, %)    
    Kinh 7 (46.7%) 11 (37.9%) 18 (40.9%) 
    Stieng 8 (53.3%) 18 (62.1%) 26 (59.1%) 
Sex (n, %)    
    Male 11 (73.3%) 22 (75.9%) 33 (75.0%) 
Mean age (SD), year 34.9 (12.2) 30.3 (10.2) 31.9 (11.0) 
Mean weight (SD), kg 58.8 (7.3) 56.2 (8.4) 57.1 (8.0) 
Mean temperature (SD), 0C 38.7 (1) 37.9 (0.9) 38.2 (1.0) 
Asexual (median, IQR), 
parasite/uL 
10,129  
[3,858;16,050] 
6,652  
[3,120;11,250] 
7,532 
[3,045;12,904] 
Positive gametocyte (n, %) 13 (86.7%) 21 (72.4%) 34 (77.3%) 
Mean G6PD activity (SD), 
IU/gHb 
8.09 (2.1) 8.6 (1.7) 8.42 (1.9) 
Mean hemoglobin level 
(SD), g/L 
133 (17.3) 131 (16.3) 132 (16.4) 
4.3.1 Hematologic safety  
The primary outcome was the occurrence of clinically relevant hemolysis in all 
subjects. The protocol-defined hemoglobin decrease criteria were hemoglobin decrease 
≥ 30% or > 30 g/L from baseline or an overall drop in hemoglobin level below 60 g/L. 
From Vietnam site, no primary-outcome event was reported in both single dose of 
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tafenoquine and 14-day course of primaquine. While in multi-site trial, the occurrence 
of decrease in the haemoglobin level were 2.4% (95% CI: 0.9 to 6.0) in the tafenoquine 
group and 1.2% (95% CI: 0.2 to 6.4) in the primaquine group. An absolute difference 
between two groups was estimated as 1.2% (95% CI: -4.2 to 5.0) [89]. All of these 
events occurred in male patients who had normal G6PD activity and did not require any 
clinical intervention. In general, patients who received tafenoquine or primaquine 
therapy shared similar haemoglobin profiles. The range and time course of mean 
changes in hemoglobin level were similar between treatment arms. After starting the 
treatment with either tafenoquine or primaquine, the haemoglobin level had a mild 
decline and decreased to the lowest point on Day 3. In the tafenoquine group, the lowest 
mean ( SD) level was 124.6  14.8 g/L, and 127.5  14.1 g/dL in the primaquine 
group. Then, these levels fluctuated within the first month post treatment period. All of 
the cases with haemoglobin decline, the level recovered spontaneously by day 29 to the 
baseline value (Figures 4.2 – 4.4).  
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Figure 4.2: Distribution of haemoglobin value in P. vivax malaria patients treated 
with CQ plus either single-dose TQ 300 mg or PQ 15 mg for 14 days. 
 
Figure 4.3: Mean change in haemoglobin from baseline in P. vivax malaria patients 
treated with CQ plus either single-dose TQ 300 mg or PQ 15mg for 14 days. 
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Figure 4.4: Percentage change in haemoglobin from baseline in P. vivax malaria 
patients treated with CQ plus either single-dose TQ 300 mg or PQ 15 mg for 14 days. 
The mean level (SD) of methaemoglobin (MetHb) was 0.53% ( 0.32) in the 
primaquine group and 0.64% ( 0.43) in the tafenoquine group. These values were not 
significantly different. After the treatment with either tafenoquine or primaquine, these 
values began to increase, with the greater extent in the primaquine group. Then, it 
reached the highest point on Day 8 in the tafenoquine group and Day 15 in the 
primaquine group (Figure 4.5). However, this increase of MetHb level following the 
treatment did not cause any clinical symptoms.  
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Figure 4.5: Mean change in absolute methaemoglobin in P. vivax malaria patients 
treated with CQ plus either single-dose TQ or PQ for 14 days. 
In the multi-site trial, two serious adverse events (pyrexia and pneumonia) that 
belonged to the tafenoquine group were reported. However, neither of these events was 
associated with a trial medication. From the Vietnam site, no death or serious adverse 
events occurred in both tafenoquine and primaquine treatment groups during the trial. 
No patient discontinued the study prematurely due to a safety event. The overall 
incidence and profile of adverse event seems comparable between the two treatment 
groups. The percentage of patients with adverse events was similar in the tafenoquine 
group (86.2% [25 of 29 patients]) and in the primaquine group (73.3% [11 of 15 
patients]). Most adverse events were mild to moderate in severity (Table 4.3). 
Although, the percentage of grade 2 adverse events in the tafenoquine group (27.6%) 
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were higher compared with those in the primaquine group (13.3%), most of the events 
were not related to the treatment medication. Laboratory investigations showed a 
transient increase in creatin phosphokinase and alanine aminotransferase with the 
severity of grade 1 or 2 in both treatment groups. One patient in the primaquine group 
was recorded a grade 3 elevation of total bilibrubin concentration. This asymptomatic 
event occurred during the first acute vivax infection and resolved within 5 days without 
any intervention. The electrocardiographic evaluation showed no prolongation in the 
QTc interval.  
Table 4.3: Frequency of all adverse events of any cause and their severity occurring 
throughout the study period (day 1 to day 180) in P. vivax malaria patients treated 
with CQ plus either single-dose TQ 300 mg or PQ 15 mg for 14 days. 
Event – n (%) patients Grade*  
Tafenoquine 
(N=29) 
Primaquine  
(N=15) 
Any adverse event Any 25 (86.2) 11 (73.3) 
 Grade 1 17 (58.6) 8 (53.3) 
 Grade 2 8 (27.6) 2 (13.3) 
 Grade 3 0 1 (6.7) 
Upper respiratory tract 
infection 
Any 2 (6.9) 3 (20) 
 Grade 1 2 (6.9) 3 (20)  
 Grade 2 0  0  
Urinary tract infection Any 1 (3.4) 2 (13.3) 
 Grade 1 1 (3.4) 2 (13.3) 
 Grade 2 0 0 
Hookworm infection Any 7 (24.1) 1 (6.7) 
 Grade 1 5 (17.2) 1 (6.7) 
 Grade 2 2 (6.9) 0 
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P. falciparum infection Any 2 (6.9) 0 
 Grade 1 1 (3.4) 0 
 Grade 2 1 (3.4) 0 
Skin infection Any 1 (3.4) 1 (6.7)  
 Grade 1 1 (3.4) 0  
 Grade 2 0  1 (6.7) 
Gastrointestinal infection  Any 1 (3.4) 0 
 Grade 1 1 (3.4) 0 
Vomiting Any 1 (3.4) 0  
 Grade 1 1 (3.4) 0  
Diarrhea Any 1 (3.4) 0  
 Grade 1 1 (3.4) 0 
Dizziness Any 3 (10.3) 0  
 Grade 1 2 (6.9) 0 
 Grade 2 1 (3.4) 0  
Pruritus Any 0 1 (6.7) 
 Grade 1 0 0  
 Grade 2 0 1 (6.7) 
Blood CPK increased Any 3 (10.3) 1 (6.7) 
 Grade 1 1 (3.4) 1 (6.7) 
 Grade 2 2 (6.9) 0  
ALT increased Any 1 (3.4) 0 
 Grade 1 0 0 
 Grade 2 1 (3.4) 0 
Blood bilirubin increased Any 0  1 (6.7) 
 Grade 3 0  1 (6.7) 
ECG QT prolongation Any 0 0 
 Grade 1 0 0 
 Grade 3 0 0 
 Grade 4 0 0 
WBC count increased Any 1 (3.4) 0 
 Grade 1 1 (3.4) 0 
Ulna fracture Any 1 (3.4) 0 
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 Grade 2 1 (3.4) 0 
Acute food poison Any  0 1 (6.7) 
 Grade 1 0 1 (6.7) 
*Common Terminology Criteria for Adverse Events v4.0  
4.3.2 Efficacy 
Relapse-free efficacy six months post-dosing is the secondary endpoint of this trial. In 
order to compare the clinical and parasitological response between tafenoquine and 
primaquine, we assessed the noninferiority of tafenoquine to primaquine in preventing 
vivax relapse after 6 months of follow-up. The proportion of patients with vivax 
recurrence per treatment arm was calculated; an odds ratio and 95% confidence interval 
were estimated. Kaplan-Meier analysis estimated the proportional hazards ratio 
between the tafenoquine and the primaquine groups. 
Table 4.4: Logistic regression analysis of recurrence-free efficacy at 6 months in P. 
vivax malaria patients treated with CQ plus either single-dose TQ 300 mg or PQ 15 
mg for 14 days.  
Outcome  Tafenoquine (N=29) Primaquine (N=15) 
Recurrence-free at month 6, n (%) 23 (79.3) 13 (86.7) 
Recurrence, n (%) 5 (17.2) 2 (13.3) 
Censored, n (%) 1 (3.5) 0 
No assessment available 1 (3.5) 0 
Odds ratio of recurrence vs. primaquine 
(95% CI)  
1.41  
(0.24, 8.34) 
Kaplan-Meier recurrence-free efficacy rate at 
month 6, % (95% CI) 
82.1  
(69.1, 97.6) 
86.7  
(71.1, 1.0) 
Hazard ratio for risk of recurrence vs. 
primaquine (95% CI)  
1.32 
(0.26, 6.78) 
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The percentage of patients who were free from recurrence over six months of 
observation was 79.3% (5 of 29 patients) in the  tafenoquine group and 86.7% (13 of 
15 patients) in the primaquine group. The calculated odds ratio of risk of recurrence 
comparing tafenoquine to primaquine was 1.41 (95% CI: 0.24 to 8.34). Kaplan-Meier 
analysis estimated of 6-month recurrence-free efficacy were 82.1% (95% CI 69.1 to 
97.6) for tafenoquine and 86.7% (95% CI 71.1 to 1.0) for primaquine (Figure 4.6). The 
proportional hazards ratio at month 6 was 13.2 (95% CI: 0.26 to 6.78). From odds ratio 
and hazards ratio comparing tafenoquine and primaquine, tafenoquine non-inferiority 
to primaquine could not be demonstrated. By 4 months of follow-up, similar analysis 
could not prove the non-inferiority in efficacy between tafenoquine and primaquine 
(Table 4.5). 
Figure 4.6: Kaplan-Meier analysis of 6-month recurrence-free efficacy for TQ versus 
PQ in P. vivax malaria patients treated with CQ plus either single-dose TQ 300 mg or 
PQ 15 mg for 14 days.  
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Table 4.5: Logistic regression analysis of recurrence-free efficacy at 4 months in P. 
vivax malaria patients treated with CQ plus either single-dose TQ 300 mg or PQ 15 
mg for 14 days. 
 
Outcome  Tafenoquine (N=29) Primaquine (N=15) 
Recurrence-free at month 4, n (%) 25 (86.2) 13 (86.7) 
Recurrence, n (%) 3 (10.3) 2 (13.3) 
Censored, n (%) 1 (3.5) 0 
Odds ratio of recurrence vs. primaquine 
(95% CI)  
1.37  
(0.19, 9.52) 
Kaplan-Meier recurrence-free efficacy rate at 
month 4, % (95% CI) 
84.6  
(56.3, 95.4) 
86.7  
(71.1, 1.0) 
Hazard ratio for risk of recurrence vs. 
primaquine (95% CI)  
1.27 
(0.29, 7.83) 
 
4.4 Discussion 
Plasmodium vivax malaria and its relapses caused by the activation of hypnozoites 
could contribute to substantial medical complications and death [175]. Primaquine is 
the only available drug that can kill the hypnozoite and has been used for over 60 years. 
In order to achieve the full efficacy, the 14-day course of primaquine is recommended 
[45]. This is one of the challenges in implementing the radical cure of primaquine in 
the malaria-endemic regions because most of the patients will not follow such a 
prolonged course of therapy when the acute symptoms have been subsided. When first 
developed in 1980s, tafenoquine possessed a long-acting pharmacokinetic property that 
could solve the potentially important problem of poor adherence by only a single dose 
course [176]. Nevertheless, like other 8-aminoquinoline, tafenoquine also cause acute 
haemolysis anemia in subjects with G6PD deficiency. In this trial, the hematologic 
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safety profile of the single-dose tafenoquine and 14-day primaquine groups was 
comparable. Both of the treatment groups caused the hemoglobin level among patients 
with normal G6PD slightly decline and then recover to baseline value within one 
month. From this multi-site trial, only one female who had moderate G6PD enzyme 
deficiency was recruited into the primaquine group. Tafenoquine has been known to 
cause haemolysis in G6PD deficient subjects [94].  In G6PD heterozygous individuals 
with intermediate activity, the decline in haemoglobin level was similar in the 
tafenoquine group (300 mg single dose) and in the primaquine group (15 mg/day x 14 
days) [174]. Thus, the haemolytic effect of tafenoquine still requires further evaluation 
in patients with P. vivax malaria and have G6PD enzyme activity less than 70% of the 
site-specific normal value. 
In Vietnam site, the recurrence free rate after 6 months of follow-up in the tafenoquine 
group (82.1%; 95% CI: 69.1 to 97.6) was lower than the rate in the DETECTIVE phase 
2b trial (89.2%; 95% CI: 77 to 95) [88]. This number in the primaquine group  (86.7%; 
95% CI:  71.1 to 1.0) was, however, higher than in phase 2b (77.3%; 95% CI: 63 to 87) 
and in the multi-site analysis (75.1%; 95% CI: 64.2 to 83.2) [89]. The non-inferiority 
of tafenoquine to primaquine could not be demonstrated in our study. This could be due 
to the directly observed therapy has been applied to all subjects participated into the 
study during the study medication period. The direct supervision of drug administration 
helps to increase the adherence of the patient and, hence might improve the antirelapse 
efficacy. Furthermore, the relapse rate of vivax malaria varied across the geographical 
location, and the higher frequency in East Asia and Oceania than elsewhere was 
reported [10, 150]. Patients from these areas required higher doses of primaquine to 
achieve the maximum radical curative efficacy [45]. In phase 2b DETECTIVE trial, a 
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clear dose-response relationship was shown [88]; therefore a higher dose of tafenoquine 
should be further evaluated in this region.  
Although, primaquine has shown its efficacy in preventing relapse, most patients with 
P. vivax malaria receive only a schizonticide owing to the fear of haemolysis and non-
adherence [158]. From our study, the single-dose tafenoquine showed no safety 
concerns when given in P. vivax malaria patients with normal G6PD activity. There 
was a possibility that primaquine offered a slight efficacy advantage over tafenoquine 
in the study population with a high compliance to the 14-day course. Nonetheless, 
extensive resources should be deployed to maintain the adherence of primaquine 
therapy. Without such interventions, adherence rates as low as 24% have been reported 
in South East Asia, with a corresponding attenuation of efficacy [68, 161]. In contrast, 
there are operational advantages to a single-dose medication, such as tafenoquine. The 
convergence of enhanced G6PD testing technology, and the convenience of single-dose 
tafenoquine present an opportunity to further examine ways to achieve an effective P. 
vivax radical cure. 
A major strength of our study is that all drugs were administered under direct 
observation from study staff during the treatment period. All of the participants 
received the full course of antirelapse therapy regardless they were randomized to either 
single-dose tafenoquine or 14-day primaquine group. This ensures the adherence of the 
subjects and can fully assess the efficacy of both treatments. However, the multi-site 
study only recruited one female subject with intermediate G6PD enzyme activity who 
was randomly assigned to the primaquine group despite an extension of the study 
recruitment window and study location to Krong Pa Medical Center, we could not 
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estimate the hemolytic safety profile of tafenoquine among patients with P. vivax 
malaria who have intermediate G6PD activity.  
 In summary, the haematologic safety profile of single-dose tafenoquine was 
comparable with the 14-day primaquine in P. vivax malaria patients with normal G6PD 
activity. Although, single 300 mg dose of tafenoquine could not show the noninferiority 
in efficacy to 14-day primaquine (0.5 mg/kg/day), the between-group difference may 
be within the range of acceptable clinical variability. With a prolonged half-life, this 
even shorter course of tafenoquine should significantly improve patient’s compliance 
and thus effectiveness of relapse prevention. 
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Chapter 5 
Prevalence and genotype of Glucose-6-phosphate dehydrogenase 
deficiency in malaria endemic regions in Vietnam 
5.1 Introduction 
Almost three billion people are at risk for Plasmodium vivax (P. vivax) infection 
globally, and outside of Africa it is the predominant cause of malaria [147]. Although 
vivax malaria was once considered a benign infection, recent evidence suggests a 
considerable morbidity and mortality, associated mainly with anaemia due to recurrent 
episodes [48, 177, 178]. The propensity for P. vivax to relapse after prolonged periods 
of aymptomatic carriage undermines the patients and healthcare providers’ perceptions 
of the importance of radical cure, and this in turn confounds malaria control and 
elimination efforts. Complete achievement of eradication of P. vivax will need the 
systematic treatment of the dormant liver forms (hypnozoites) of the parasite.  
The only class of anti-malarial drugs currently available to eliminate the hypnozoites 
are the 8-aminoquinoline compounds and these cause haemolysis in glucose-6-
phosphate dehydrogenase deficiency (G6PDd) individuals [151]. The degree of 
haemolysis depends on total dose of primaquine (PQ), underlying G6PD variant and 
age of the red blood cell (RBC) population (with lower G6PD activities in older cells) 
[76]. Primaquine-based radical cure in G6PD normal patients is usually administered 
over 14 days at a total dose of either 3.5 or 7 mg/kg bodyweight depending on the 
assumed susceptibility of dominant local parasite strains [179]. Although either PQ 
regimen is usually well tolerated in G6PD normal subjects, it is often not prescribed 
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due to fears of drug-induced haemolysis. Moreover, when the long treatment course of 
PQ is precribed the long treatment course, which is normally 14 days, can be associated 
with poor adherence and thus effectiveness [180]. Tafenoquine (WR 238605), another 
8-aminoquinoline, was discovered by scientists at the Walter Reed Army Institute of 
Research in 1978, and has been approved by the Food and Drug Administration in 2018 
[181]. The half-life of Tafenoquine (TQ) is 14 days compared to 4-6 h for PQ, and this 
allows adequate cure with a single 300mg dose [88]. With the prolonged halflife, this 
is the alternative intervention for the treament and relapse prevention of P. vivax 
malaria. A single dose regimen of TQ is likely to improve treatment adherence 
significantly, however may also raise the potential for sustained haemolysis in G6PDd 
patients and for this reason TQ is likely to be ready for use only after G6PD normal 
status has been confirmed. 
Gucose-6-phosphate dehydrogenase deficiency (G6PDd) is an X-linked disorder of the 
red blood cells common in malaria endemic countries [100]. G6PD is an essential 
enzyme in the pentose phosphate pathway (PPP), the only pathway for human RBC to 
maitain the cells’ redox potential by reducing NADP+ to NADPH [97]. Non-
synonymous mutations in the gene can decrease enzyme activity or reduce the stability 
of the enzyme, resulting in different degrees of G6PD deficiency [102]. The loss of 
G6PD enzyme activity is associated with the reduced response of red blood cells when 
exposed to oxidative stress such as fava beans ingestion, certain medicines or infections 
[97]. The prevalence of this enzymopathy is different among regions and populations, 
commonly seen tropical and sub-tropical areas [101]. Since the gene is located on the 
X chromosome, males are hemizygous and are either classified as phenotypic G6PD 
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deficient or normal. Females, on the other hand, can be homozygous deficient (two 
gene copies with a deleterious mutation), homozygous normal with both gene copies 
expressing G6PD variants, or heterozygous (one gene copy encoding a normal G6PD 
variant and one gene copy encoding a deficient G6PD variant) [182]. As a consequence, 
phenotypic G6PD activities in heterozygous females can manifest in a wide range from 
deficiency to normal status. This could pose challenges to the accurate diagnosis in 
current tests to detect G6PD deficiency. More than 400 variants of G6PD have been 
described [96]. The two most common G6PDd variants are the G6PD A- and G6PD 
Mediterranean variants. G6PD A- is common across the African continent and is 
categorised as a Class III deficiency, whereas G6PD Mediterranean is common among 
Italians, Arabs, and Jews, and is categorised as a Class II deficiency. In Southeast Asia, 
the most common variant in Myanmar and Thailand is G6PD Mahidol (Class III), 
whereas in Laos and Cambodia, the most common variant is G6PD Viangchan (Class 
II) [95]. 
The G6PD deficiency distribution strongly differs from one ethnic group to another, 
and geographical location. It was suggested that G6PD deficiency confers resistance to 
falciparum malaria since the highest frequencies were found among populations living 
in endemic areas [183]. In Viet Nam, different studies have been conducted to 
investigate the G6PD deficiency status in hemolytic subjects as well as mutations in 
G6PD gene in many regions [184-187]. The prevalence of G6PD deficiency varies 
among different regions and different ethnic populations, commonly from 8.7% to 
14.0% [186]. These studies have found common causative mutations for G6PD 
deficiency in some provinces and ethnic populations such as Kinh and other populations 
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in Lam Dong, Kinh in Ho Chi Minh city, and S’tieng in Binh Phuoc. In 2013, two 
causative mutations of the G6PD deficiency in Kinh population have been determined 
including Viangchan (871G>A) and Canton (1376G>T). These two missense mutations 
have been screened and occurred with high frequencies in the G6PD deficient patients 
according to the study in Lam Dong province and Ho Chi Minh city. The other 
mutations G6PD Kaiping (1388G>A), G6PD Union (1360C>T) were also detected 
[184]. In these studies, the mutation G6PD Mahidol (487G>A) has not been detected 
[187]. In central and northern Vietnam, G6PD Viangchan was found to be dominant, 
followed by G6PD Canton [185]. In order to promote the radical treatment in P. vivax 
malaria elimination target, our objective of this study is to assess the prevalence of 
G6PD deficiency and to identify the most common variants causing G6PD deficiency 
in populations living in malaria endemic regions in Vietnam.  
5.2 Methods  
5.2.1 Survey design and sample collection 
This was a cross sectional survey conducted in villages in Dak O commune, Binh Phuoc 
province and in Phuoc Ha commune, Ninh Thuan province in Vietnam [188]. The 
villages were selected based on parasite prevalence, enthusiasm of villagers to 
participate, and access. In 2015, in Dak O commune, the annual malaria incidence was 
25 P. falciparum cases and 17 P. vivax cases in 1000 people. While, in Phuoc Thang 
commune, the values were 24 P. falciparum cases and seven P. vivax cases in 1000 
people. The inhabitants of six villages were invited to participate in baseline and 
subsequent 3-monthly surveys up to 24 months, which included the collection of venous 
blood samples to investigate the asymptomatic P. falciparum malaria infections in the 
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regions. These blood samples were analyzed to detect submicroscopic malaria and 
G6PD testing. G6PD deficiency was determined by FST at recruitment. The G6PD 
study protocol was reviewed and approved by the Institute of Malariology, Parasitology 
and Entomology in Ho Chi Minh City (185/HDDD), the Institute of Malariology, 
Parasitology and Entomology in Quy Nhon, and the Oxford Tropical Research Ethics 
Committee (1015-13). The written informed consent was obtained from subjects aged 
more than 16 years and parental or guardian consent was obtained if subject was 
children less than 16 years.  
5.2.2 Laboratory methods 
Samples collected during population surveys were analyzed for G6PD phenotype using 
the FST (R&D Diagnostic, Greece) following manufacturer’s instruction [189]. The 
FST was performed as semi-quantitative test thus allowing intermediate results to be 
reported. Blood was collected onto filter paper and DNA extracted using DNA Blood 
mini kits (Qiagen, Germany). Genotyping was performed in method like this. Samples 
tested with FST and detected as G6PD deficient or G6PD intermediate were analyzed 
by Polymerase Chain Reaction – Restriction Fragment Length Polymorphism (PCR-
RFLP) for a panel of four mutations: Viangchan, Union, Canton, Kaiping.  
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Table 5.1: Primers sequences, restriction enzymes and annealing temperatures of 
PCR-RFLP protocol used. 
Assay Oligonucleotides Tann Restriction 
enzyme 
Reference 
Viangcha
n  
5’-CCTGAGGGCTGCACATCT-
3’ 
5’-
GTCGTCCAGGTACCCTTTGGG
G-3’ 
64°C Hpy 188III - 
Union 
5’-
ACGTGAAGCTCCCTGACGC-3’ 
5’-
GTGAAAATACGCCAGGCCTT
A-3’ 
58°C 
Hha I 
Huang et al., 
1996 
Canton 
5’-
ACGTGAAGCTCCCTGACGC-3’ 
5’-
GTGAAAATACGCCAGGCCTT
A-3’ 
58°C 
Afl II 
Huang et al., 
1996 
Kaiping 
5’-
ACGTGAAGCTCCCTGACGC-3’ 
5’-
GTGCAGCAGTGGGGTGAACA
TA-3’ 
58°C 
Nde I 
Huang et 
al., 1996 
5.2.3 Statistical analysis 
The data was collected and built in Excel database. The variables included sample ID, 
gender, FST phenotype, genotype (when available), and village/province name. 
5.3 Results  
From December 2013 to January 2016, a total of 1915 blood samples were collected 
during several population surveillances in 6 villages in Binh Phuoc and Ninh Thuan 
provinces. Of which, 908 (47.4%) samples were from males. The G6PD deficiency 
status was identified by FST method at enrollment.    
The overall prevalence of G6PD deficiency detected by fluorescent spot test (FST) in 
samples collected was 6.5% (125 of 1915). When stratified by gender, this prevalence 
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was 8.6% (78 of 908) in males and 4.7% (47 of 1007) in females. Additionally, 118 
(6.2%) samples was detected as “intermediate”, in which 51 (5.6%) were in males and 
67 (6.7%) in females (Table 5.2).  
Table 5.2: Results of the fluorescent spot test (FST) by gender 
FST results Males (%) Females (%) Total (%) 
Deficient 78 (8.6) 47 (4.7) 125 (6.5) 
Intermediate 51 (5.6) 67 (6.7) 118 (6.2) 
Normal 779 (85.9) 893 (88.6) 1672 (87.3) 
Total 908 (47.4) 1007 (52.6) 1915 (100) 
 
The prevalence of G6PD deficiency detected by either FST or inferred from genotype 
increased to 8.3% (158 of 1915). By provincial level, this study showed variable 
frequency among different regions in country. The prevalence of G6PD deficiency were 
6.6% and 10.1% in Binh Phuoc and Ninh Thuan province, respectively. This difference 
was statistically significant (p < 0.05). At village level, the prevalence of G6PD 
deficiency changed at even greater variability. They were 11.7% in Gia, 10% in Tra 
No, 9.2% in Tan Ha, 8.8% in Bu Bung and 4.3% in Bu Khon. These prevalence was 
significant different between village Bu Khon and other villages (Gia, Tra No, Tan Ha 
and Bu Bung). While in La A village, no G6PD deficient sample was recorded in La A 
(Table 5.3).  
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Table 5.3: The prevalence of G6PD deficiency by village level 
Site Province 
Samples analyzed 
G6PD deficiency  
Male Female Total 
Bu Bung  Binh Phuoc 243 256 499 44 (8.8) 
Bu Khon  Binh Phuoc 262 246 508 22 (4.3) 
Gia  Ninh Thuan  217 294 511 60 (11.7) 
La A Ninh Thuan  25 27 52 0 (0) 
Tan Ha Ninh Thuan  137 158 295 27 (9.2) 
Tra No Ninh Thuan  24 26 50 5 (10.0) 
Total   908 1007 1915 158 (8.3) 
The prevalence of G6PD variants was described in Table 5.4. Viangchan variant was 
found to be the most frequent variant among those analyzed, accounting for 96.4% of 
all mutations found. Union variant only had only 0.4% of the samples analyzed. 
Although, Union and Kaiping variants were investigated, no mutation was found.  
Table 5.4: Distribution of the G6PD variants by gender and genotype 
Gender  Genotype  
G6PD variants % 
carriers  Total  Viangchan  Union  Canton  Kaiping  
Male  Hemizygote 52 50 2 - - 5.7 
Female  Homozygote 13 13 - - - 1.3 
 Heterozygote 45 43 2 - - 4.5 
A dash indicates that a mutation was not found  
5.4 Discussion 
The assessment of the prevalence of G6PD deficiency and identification of the mutation 
are essential to implement the effective 8-aminoquinoline agents in order to achieve the 
radical cure of P. vivax malaria. In this study, based on the determination of G6PD 
deficiency by FST criteria, we found that the prevalence of G6PD deficiency was 6.5% 
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in malaria endemic regions. Our finding demonstrated a high variability of G6PD 
deficiency prevalence among different regions. The prevalence ranged from 0% in La 
An village to 11.7% in Gia village.  In 2009, a community based study in minority 
ethnic male in Central and Northern of Vietnam found that the prevalence of G6PD 
deficiency was 4.0% [185]. Another survey in Lam Dong province showed this 
prevalence was 2.3% [187]. This variability was also observed in Venezuela [190], in 
India [191] and in several malaria endemic countries [182].  
Although four mutations were studied for G6PD genotype, Viangchan variant was 
observed at a highest prevalence (96.4%). From previous study, this mutation was 
known as the most common G6PD deficient variant in the Vietnamese population [184, 
187, 192]. Not only in Vietnam, G6PD Viangchan is also considered a dominant variant 
in Southeast Asia as well [193-195]. Moreover, the hemolytic risk in subjects with 
G6PD-Viangchan and Mahidol mutation following 8-aminoquinolines treatment has 
been described [174, 196, 197]. The finding of high frequency of Viangchan mutation 
accompanied with its hemolytic risk in patients has a number of clinical implications. 
It is important to determine the G6PD status in patients before taking any radical 
therapy. Especially, in women with G6PD heterozygote genotype, G6PD testing in the 
field needs to accurately identify the intermediate G6PD phenotype.  
Our findings present several limitations. Firstly, the study was based on population 
surveys however the analyzed samples came from within two malaria endemic regions. 
This sampling method could therefore not able to generalize the overall prevalence of 
G6PD deficiency. Secondly, the results from FST test could not adequately interpret 
the deficient status in case of heterozygous woman with intermediate G6PD activity. 
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Thirdly, with high molecular heterogeneity in the G6PD gene in Southeast Asia [95], 
the other mutation might be missed if only four variants were investigated.  
In summary, in two malaria endemic provinces in Vietnam, the prevalence of G6PD 
deficiency was around 10%, with a high proportion of Viangchan variant. The 
substantial reliable G6PD testing is a consideration when applying the radical cure of 
P. vivax malaria.  
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Chapter 6 
Discussion 
6.1 Short course of primaquine and the radical cure of vivax 
Since 1990s, Vietnam has made tremendous progress in reducing the mortality and 
morbidity related to malaria [198]. Thanks to the large scale implementation of control 
intervention such as insecticide-treated bed nets, indoor residual spraying, and prompt, 
free-of-charge diagnosis and treatment, the number of cases fell from 130,000 in 2004 
to 6,870 in 2018 with one recorded death [11]. The Vietnamese government is aiming 
to achieve national malaria elimination by 2030 in accordance with the GMS regional 
malaria elimination strategy [199]. In Vietnam, malaria still persists at low prevalence 
mainly in remote mountainous and forested areas, inhabited by ethnic minority 
populations. The ethnic minorities carry a large share of malaria burden related to their 
remote settlements and the need to make a living with forested activities [200-202]. Our 
study found that most malaria patients were males who mostly worked outdoors in 
borderline areas. This increases the risk to acquiring mosquito bites and infection with 
the P. vivax parasite. Forest malaria has a major role on malaria burden and constitute 
challenge in controlling malaria [200, 202]. As malaria control accelerates, the P. vivax 
proportion in co-endemic areas tends to rise compared to that of P. falciparum [151]. 
In Viet Nam, recently, this ratio P. vivax and P. falciparum has increased gradually. In 
2018, from report of National Malaria Control Programme, the incidence of falciparum 
and vivax malaria was accounted for 61% and 36% of malaria cases, respectively [11]. 
The morbidity and mortality of P. vivax have been underestimated, with evidence of 
fatality and other comorbidities like malnutrition, HIV, or coinfection [10, 203]. P. 
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vivax infection in childhood or pregnancy is also associated maternal anemia, 
spontaneous abortion, low birthweight and health development [204, 205]. Possessing 
distinguishable characteristics, P. vivax has the property to develop the liver-stage, 
hypnozoites, which can cause multiple relapses. This special feature makes its control 
more difficult to achieve [9]. Geographically, there are high variability in the 
prevalence of P. vivax strains accompanied with its latency, likelihood of relapse and 
frequency of relapse [150].  Strains in found in Southeast Asia and Oceania have the 
shortest latency time to relapse [10]. For all of these reasons, the task of vivax relapse 
prevention needs to be addressed and prioritized in order to eliminate P. vivax.  
People with P. vivax malaria require treatment with an antimalarial drug to treat the 
blood-stage infection, and a drug to treat the hypnozoite stage to complete the radical 
cure. Recommendations from WHO include the combination of the chloroquine or an 
artemisinin-based combination therapy for the blood-stage infection and 0.25 to 0.5 
mg/kg/day primaquine for 14 days for the liver stage [45]. Radical cure can only be 
achieved when the antirelapse therapy is effective. However, the long duration of 14 
days can affect the compliance of patients when the acute symptoms have subsided. 
The determinant of efficacy of primaquine treatment is the total dose rather than the 
length of the course [159], whereas the adverse reactions are mostly associated with the 
daily intake [151]. If a higher dose of primaquine could be administered safely over a 
shorter period of time, it may improve adherence rates. Our findings showed the 
efficacy of the short 7-day primaquine course was non-inferior to the standard 14-day 
course in vivax patients with normal G6PD. It is clear that primaquine treatment with 
total dose of 7 mg/kg demonstrated the substantial clinical benefit by preventing vivax 
relapse in malaria endemic regions. If no hypnozoiticidal agents were prescribed for 
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patients with P. vivax infection, the relapse rate could be as high as 50%. The major 
concern of 8-aminoquinoline drugs is the haemolytic risk, especially in G6PD 
deficiency. This study has shown the haemoglobin levels of G6PD-normal subjects did 
not differ significantly between two regimens of primaquine during drug administration 
time. Consequently, it might be safe to prescribe 7-day high dose primaquine for vivax 
patients. The most observed complaints in short course were related to gastrointestinal 
disturbance. These symptoms can be relieved if the drugs are co-administered with 
food. In malaria field settings, with available point of care G6PD testing, the short 
course of primaquine will offer affordable choice in facilitating the radical cure of P. 
vivax malaria.   
The adherence to antimalarial drugs is a major care in malaria endemic areas with low 
level of health capacity and living standard. Our own experiences with falciparum 
malaria have shown that the compliance with “more than 3-day regimens” are usually 
poor. The adherence of short course 7-day of primaquine without direct supervision is 
still unknown. Further studies are needed to assess this point. Another issue that could 
be confronted is that the metabolism of primaquine is affected by the cytochrome P450 
(CYP) 2D6 enzyme activity [58]. Human CYP2D6 is highly polymorphic, and 
decreased CYP2D6 enzyme activity has been linked to decreased primaquine 
antimalarial activity [87]. In any case of series relapses of vivax malaria despite fully 
administered dosage of primaquine, the testing of CYP2D6 activity should be 
considered.  
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6.2 Single dose of tafenoquine and the radical cure of vivax 
Tafenoquine, another 8-aminoquinoline derivative, was developed in the 1980s as an 
alternative to primaquine under the collaboration of Glaxo Smith Kline Pharmaceutical 
company and Medicines for Malaria Venture [77, 206]. The major advantage of 
tafenoquine is a long terminal elimination half-life which allows a single dose to be 
given. The efficacy of its antirelapse property against P. vivax hypnozoite has been 
described recently in large clinical trials [88, 164]. Overall, tafenoquine at a 300 mg 
single dose was highly efficacious in preventing P. vivax recurrences until 6 months 
after treatment. The relapse free percentage was 63% (95% CI: 55 to 69) for 
chloroquine plus tafenoquine compared to 28% (95% CI: 20 to 36) for chloroquine 
alone [88]. In July 2018, the US Food and Drug Administration has approved single 
dose of 300 mg tafenoquine can be used combined with chloroquine for a radical cure 
of Plasmodium vivax malaria in patient more than 16 years old [181].  
The side effect profile of tafenoquine is similar to primaquine. Generally, tafenoquine 
was generally well tolerated. The most frequent complaint was gastrointestinal 
abnormalities (nausea and abdominal pain) [91]. The ophthalmic safety of single dose 
tafenoquine 300 mg has been assessed. Mild vortex keratopathy, corneal deposits was 
detected in 93% of subjects taking tafenoquine. This disturbance did not associate with 
any effect on visual acuity and was fully recovered in all subjects by one year [92]. 
Prolongation of the QT interval is one of the issues in patients treated with antimalarial 
drugs. Approximately 2% of patients in taking tafenoquine experienced QT 
prolongation [88] or no case even at a dose of 1,200 mg [207]. The major safety concern 
with tafenoquine, like primaquine, is drug-induced hemolysis in patients with G6PD 
enzyme deficiency. The effects of tafenoquine in G6PD deficient heterozygotes were 
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reported [174]. The level of hemolysis was dose-dependent with greater haemoglobin 
reductions in patients receiving 300 mg compared to those receiving 200 mg or 100 mg. 
The hematological safety profile was similar between heterozygote females who 
received either 300 mg single dose of tafenoquine or 15 mg primaquine for 14 days 
[174].  These females did not develop clinical symptoms and require any intervention. 
Primaquine with rapid elimination, can be easily stopped as soon as the first sign of 
hemolysis is suspected, whereas with longer half-life, tafenoquine can risk any subjects 
with G6PD deficiency after drug administration.  
From this trial, regards to safety concern, 300 mg single-dose of tafenoquine was 
demonstrated to have the comparable characteristics with those of 14-day primaquine 
course. Although, the non-inferiority of efficacy between tafenoquine and primaquine 
could not be proved, the clinical significance of tafenoquine still existed. The 
convenient practical tafenoquine regimens potentially will improve drug effectiveness 
due to increased adherence, in contrast to primaquine where adherence is challenged 
by long period of daily dosing. The implementation of tafenoquine, a newly registered 
antihypnozoite drug, in the national malaria control programme has a number of 
considerations: 1) the cost effectiveness balance of tafenoquine treatment in vivax 
patients; 2) the available and reliable point of care quantitative G6PD diagnostic test. 
Previously, the cost-effectiveness analyses of tafenoquine have not been made yet. 
Until recently, the study in Serbia has been conducted to compare the cost-utility of 
tafenoquine versus primaquine for the radical cure of vivax malaria [208]. From this 
study, tafenoquine was shown to be cost-effective in comparison to primaquine for the 
radical cure. However, this study has not evaluated the cost of G6PD testing, a major 
part in implementing tafenoquine.  
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6.3 G6PD deficiency and radical cure of vivax malaria 
The presence of G6PD deficiency is a major operational obstacle to the implementation 
of antihypnozoite therapy with 8-aminoquinolines. G6PD deficiency is the most 
common enzymopathy worldwide affecting approximately 400 million people, the 
majority of whom are at risk for malaria [95]. As G6PD deficiency is known to be 
associated with protection against malaria [209], its prevalence in P. vivax patients is 
expected to be lower than in the general population. The prevalence and genetic variants 
of G6PD deficiency in Asia were found to be heterogeneous [96].  Therefore, the risk-
benefit ratio balance should be considered when implementing the 8-aminoquinoline 
therapy. The overall prevalence of G6PD deficiency allele across malaria-endemic 
countries is estimated to be 8.0% [182]. The prevalence of G6PD deficiency in several 
malaria regions in Vietnam changes variously from 0% up to 11% [184, 185, 192]. The 
distribution of G6PD deficiency phenotypes varies dependent upon the ethnic groups. 
The malaria burden in Viet Nam is associated with forested areas, where most of the 
people are various ethnic minorities, e.g., S’tieng, J’rai, Tay, and M’nong. The 
prevalence of G6PD deficiency in these populations needs to be identified before 
implementing antirelapse interventions. The risk-benefit ratio balance should be 
considered what kind of the 8-aminoquinoline therapies could be carried out. In terms 
of the G6PD genetic mutations, there was a great change in variants and increased 
diversity across countries. Our study showed G6PD Viangchan were the most common 
variants in malaria regions, although more specific primers are needed to find out other 
variants. G6PD Mahidol and Viangchan variants were very common among 
communities in Myanmar, Thai populations [96]. The dependency of the risk and 
severity of hemolysis anemia on G6PD variants is highly variable. Mild, limited 
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hemolysis has been demonstrated in hemizygous males with the African G6PD – 
variant, the Mahidol variant, and the Viangchan variant [210] and in heterozygous 
females with the G6PD Mahidol or G6PD Viangchan variant [50, 197] .  
6.4 Conclusion 
Over the past 90 years 8-aminoquinolines have been prescribed mostly without testing 
for G6PD deficiency: initially, because this enzyme defect was unknown; and 
subsequently because it was largely disregarded. Nowadays there is increasing 
deployment of semi-quantitative tests, which identify male hemizygotes and female 
homozygotes, but fail to identify a substantial proportion of female heterozygotes. At 
the moment, for most malaria-endemic areas where testing is unavailable and 
primaquine is the only option, radical treatment requires a careful appraisal of risks and 
benefits, consideration of safer treatment regimens, and education of the patient to stop 
taking primaquine if adverse effects occur. This risk-benefit assessment requires 
knowledge of local relapse patterns and of G6PD variants and their severity, and of the 
availability of medical supervision and access to facilities for blood transfusion. In the 
future it is hoped that point of care quantitative tests will be developed and deployed in 
malaria field settings. This will provide accurate assessment of the phenotype of G6PD 
status, and thus of the potential severity of haemolysis, which is roughly inversely 
proportional to G6PD activity: the lower the activity, the more severe the haemolysis. 
These tests will be especially necessary for the safe use of tafenoquine. Currently, some 
promising point of care quantitative G6PD tests are under investigation [117, 211]. 
However, no rapid G6PD diagnostic test used in malaria field settings is officially 
recommended in Vietnam. During the awaiting time until G6PD tests are available and 
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affordable, both clinicians and patients should be counselled the signs of hemolysis 
(dark-coloured urine and jaundice) and signs and symptoms of anemia (pallor, fatigue, 
dyspnea with mild exertion). This careful clinical monitoring can be applied to patients 
who are prescribed primaquine treatment, but not for single dose tafenoquine, which 
requires more accurate value of G6PD enzyme activity. 
Following the success in national malaria control programme, Viet Nam officially 
engaged into malaria elimination by 2030. Consequently, the programme has shifted 
from control to elimination strategies. Plasmodium vivax and Plasmodium falciparum 
malaria are the two main species in Viet Nam. Universal treatment that could cure 
patients with uncomplicated malaria due to either P. vivax or P. falciparum may offer 
significant benefits. More feasible options of antirelapse treatment have been 
demonstrated with comparable efficacy and acceptable safety profile. A strategy of 
combining an ACT to treat the asexual stages of all Plasmodium species and a 
hypnozoiticidal agent (short course of primaquine or single dose of tafenoquine) to 
prevent relapse of P. vivax could be a plausible approach. 
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